| 1 | Early-onset atherosclerotic cardiovascular disease | 2.0 | 33 | Citations (PDF) |
| 2 | Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry | 2.2 | 1 | Citations (PDF) |
| 3 | Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study | 4.0 | 5 | Citations (PDF) |
| 4 | Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA | 1.5 | 15 | Citations (PDF) |
| 5 | Inflammatory markers and calcification of coronary arteries, aorta and cardiac valves: Findings from the atherosclerosis risk in communities study | 2.8 | 6 | Citations (PDF) |
| 6 | An overview of persistent chylomicronemia: much more than meets the eye | 2.2 | 15 | Citations (PDF) |
| 7 | County-level association between modifiable health behaviors and premature mortality in the United States | 1.6 | 0 | Citations (PDF) |
| 8 | Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial | 4.0 | 15 | Citations (PDF) |
| 9 | Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia | 2.3 | 17 | Citations (PDF) |
| 10 | Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system | 3.1 | 10 | Citations (PDF) |
| 11 | A Meta-Analysis and Systematic Review of Cardiac Troponin I vs T in Community Dwelling Adults: Is Specificity at Risk? | 1.1 | 6 | Citations (PDF) |
| 12 | Recognition and management of persistent chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology | 3.1 | 9 | Citations (PDF) |
| 13 | Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups | 4.4 | 6 | Citations (PDF) |
| 14 | From Trials to Practice: Implementing a Clinical Intervention in Community Settings | 1.9 | 1 | Citations (PDF) |
| 15 | Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi‐Ethnic Study of Atherosclerosis: The Pooling Project | 4.0 | 6 | Citations (PDF) |
| 16 | The impact of genetic testing on physician practice in specialized cardiovascular clinics | 3.1 | 0 | Citations (PDF) |
| 17 | † Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia | 3.1 | 0 | Citations (PDF) |
| 18 | LDL cholesterol management simplified in adults—Lower for longer is better: Guidance from the National Lipid Association | 3.1 | 13 | Citations (PDF) |
| 19 | Glycerol Kinase Gene Variant as a Cause of Pseudohypertriglyceridemia and Apparent Poor Response to Plozasiran 2025, 3, | | 0 | Citations (PDF) |
| 20 | Heart Failure and Death in Older Adults With Elevated Cardiac Biomarkers But Without Risk Factors: The Atherosclerosis Risk in Communities Study | 4.0 | 0 | Citations (PDF) |
| 21 | Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia | 3.1 | 1 | Citations (PDF) |
| 22 | A machine learning-based approach to identify peripheral artery disease using texture features from contrast-enhanced magnetic resonance imaging | 1.8 | 10 | Citations (PDF) |
| 23 | Reinstating LDL-C Measurement as a Quality Metric | 1.3 | 2 | Citations (PDF) |
| 24 | High-Sensitivity Cardiac Troponins I and T and Cardiovascular Outcomes: Findings from the Systolic Blood Pressure Intervention Trial (SPRINT) | 1.1 | 5 | Citations (PDF) |
| 25 | Trends in sleep apnea and heart failure related mortality in the United States from 1999 to 2019 | 3.0 | 7 | Citations (PDF) |
| 26 | Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States | 4.0 | 5 | Citations (PDF) |
| 27 | Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development | 13.7 | 11 | Citations (PDF) |
| 28 | Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial | 2.2 | 28 | Citations (PDF) |
| 29 | Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development | 13.7 | 59 | Citations (PDF) |
| 30 | Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury | 33.0 | 77 | Citations (PDF) |
| 31 | Intensive Blood Pressure Lowering in Individuals With Low Diastolic Blood Pressure and Elevated Troponin Levels in SPRINT | 4.0 | 2 | Citations (PDF) |
| 32 | Galectin‐3, Metabolic Risk, and Incident Heart Failure: The ARIC Study | 4.0 | 9 | Citations (PDF) |
| 33 | Global burden of cardiovascular disease attributable to smoking, 1990–2019: an analysis of the 2019 Global Burden of Disease Study | 2.0 | 44 | Citations (PDF) |
| 34 | Oral PCSK9 Inhibitors | 4.7 | 19 | Citations (PDF) |
| 35 | High lipoprotein(a): Actionable strategies for risk assessment and mitigation | 2.8 | 59 | Citations (PDF) |
| 36 | SYNERGISTIC EFFECT OF OBICETRAPIB AND EZETIMIBE ON CIRCULATING LDL PARTICLES | 2.3 | 2 | Citations (PDF) |
| 37 | GLOBAL BURDEN OF CARDIOVASCULAR DISEASE ATTRIBUTABLE TO SMOKING, 1990-2019; AN ANALYSIS OF 2019 GLOBAL BURDEN OF DISEASE STUDY | 2.3 | 3 | Citations (PDF) |
| 38 | COMPARING LIPOPROTEIN (A) MEASUREMENT IN MG/DL VS NMOL/L IN THE BIRACIAL ATHEROSCLEROSIS RISK IN COMMUNITY COHORT | 2.3 | 0 | Citations (PDF) |
| 39 | REDUCTIONS IN LDL-C WITHIN THE FIRST YEAR OF TREATMENT WITH INCLISIRAN: RESULTS FROM A MULTICENTER REAL WORLD COHORT | 2.3 | 1 | Citations (PDF) |
| 40 | Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia | 11.1 | 158 | Citations (PDF) |
| 41 | Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort | 2.3 | 88 | Citations (PDF) |
| 42 | The multifaceted life of macrophages in white adipose tissue: Immune shift couples with metabolic switch | 6.4 | 6 | Citations (PDF) |
| 43 | It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States | 2.5 | 12 | Citations (PDF) |
| 44 | Individual and Joint Associations of High‐Sensitivity Troponin I and High‐Sensitivity Troponin T with Cardiac Phenotypes and Outcomes in the General Population: An Analysis From the Dallas Heart Study | 4.0 | 5 | Citations (PDF) |
| 45 | Contrast-Enhanced Magnetic Resonance Imaging Based T1 Mapping and Extracellular Volume Fractions Are Associated with Peripheral Artery Disease | 1.4 | 0 | Citations (PDF) |
| 46 | Bempedoic Acid Falls in Line | 2.3 | 1 | Citations (PDF) |
| 47 | High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT | 6.6 | 7 | Citations (PDF) |
| 48 | Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study | 18.0 | 12 | Citations (PDF) |
| 49 | Circulating Blood Plasma Profiling Reveals Proteomic Signature and a Causal Role for SVEP1 in Sudden Cardiac Death | 2.9 | 3 | Citations (PDF) |
| 50 | Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis | 13.7 | 40 | Citations (PDF) |
| 51 | NT-proBNP and Cardiac Troponin I, but Not Cardiac Troponin T, Are Associated With 7-Year Changes in Cardiac Structure and Function in Older Adults: The ARIC Study | 18.0 | 20 | Citations (PDF) |
| 52 | Should We Recommend Vitamin K2 Supplement to Prevent Coronary Artery Calcification for Patients Receiving Statins and/or Warfarin? | 2.1 | 1 | Citations (PDF) |
| 53 | Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults | 1.8 | 8 | Citations (PDF) |
| 54 | Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking | 4.0 | 16 | Citations (PDF) |
| 55 | Clonal hematopoiesis of indeterminate potential and cardiovascular disease | 4.0 | 13 | Citations (PDF) |
| 56 | Renin: Measurements, Correlates, and Associations With Long-Term Adverse Kidney Outcomes | 2.0 | 5 | Citations (PDF) |
| 57 | Severe hypercholesterolemia in a patient with very low albumin and normal renal function | 3.1 | 5 | Citations (PDF) |
| 58 | A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study | 2.4 | 7 | Citations (PDF) |
| 59 | Sex‐related differences in premature cardiovascular disease in familial hypercholesterolemia | 3.1 | 26 | Citations (PDF) |
| 60 | Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study | 1.1 | 75 | Citations (PDF) |
| 61 | Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT | 18.0 | 19 | Citations (PDF) |
| 62 | Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease | 18.0 | 20 | Citations (PDF) |
| 63 | Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial | 3.1 | 61 | Citations (PDF) |
| 64 | Clonal haematopoiesis and risk of chronic liver disease | 37.9 | 194 | Citations (PDF) |
| 65 | Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project | 1.5 | 32 | Citations (PDF) |
| 66 | Magnetic Resonance Imaging‐Derived Microvascular Perfusion Modeling to Assess Peripheral Artery Disease | 4.0 | 6 | Citations (PDF) |
| 67 | Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT | 4.0 | 24 | Citations (PDF) |
| 68 | Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study | 4.5 | 12 | Citations (PDF) |
| 69 | Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial | 33.0 | 126 | Citations (PDF) |
| 70 | Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 | 2.3 | 185 | Citations (PDF) |
| 71 | Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities Study | 4.0 | 5 | Citations (PDF) |
| 72 | Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease | 6.6 | 8 | Citations (PDF) |
| 73 | Lipid-Lowering Therapy in the Elderly | 2.3 | 5 | Citations (PDF) |
| 74 | Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study | 4.4 | 32 | Citations (PDF) |
| 75 | Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry | 4.0 | 46 | Citations (PDF) |
| 76 | Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial | 3.1 | 78 | Citations (PDF) |
| 77 | Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study | 2.0 | 65 | Citations (PDF) |
| 78 | Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials | 1.5 | 8 | Citations (PDF) |
| 79 | Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease | 18.0 | 12 | Citations (PDF) |
| 80 | Omega-3 Fatty Acids and Risk for Atrial Fibrillation | 2.3 | 6 | Citations (PDF) |
| 81 | Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life | 12.5 | 130 | Citations (PDF) |
| 82 | RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts | 33.0 | 93 | Citations (PDF) |
| 83 | FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome | 0.3 | 0 | Citations (PDF) |
| 84 | Midlife Systemic Inflammatory Markers Are Associated With Late-Life Brain Volume | 1.0 | 3 | Citations (PDF) |
| 85 | Circulating Neutrophil-Related Proteins Associate with Incident Heart Failure and Cardiac Dysfunction: The ARIC Study | 7.3 | 13 | Citations (PDF) |
| 86 | MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study | 4.4 | 16 | Citations (PDF) |
| 87 | Implementation and Evaluation of a mHealth-Based Community Health Worker Feedback Loop for Hispanics with and at Risk for Diabetes | 2.4 | 14 | Citations (PDF) |
| 88 | Social Vulnerability and Cardiovascular-Related Mortality Among Older Adults in the United States | 2.0 | 7 | Citations (PDF) |
| 89 | Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020 | 11.1 | 26 | Citations (PDF) |
| 90 | Novel Size‐Based High‐Density Lipoprotein Subspecies and Incident Vascular Events | 4.0 | 14 | Citations (PDF) |
| 91 | County‐Level Cardiologist Density and Mortality in the United States | 4.0 | 11 | Citations (PDF) |
| 92 | Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn | 2.5 | 10 | Citations (PDF) |
| 93 | The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour | 0.4 | 2 | Citations (PDF) |
| 94 | Inclisiran | 2.3 | 2 | Citations (PDF) |
| 95 | Longitudinal Magnetic Resonance Imaging–Based Superficial Femoral Artery Velocity Measurements in Diabetic and Nondiabetic Patients With Peripheral Artery Disease | 0.7 | 0 | Citations (PDF) |
| 96 | Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study | 2.0 | 34 | Citations (PDF) |
| 97 | Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey | 1.5 | 18 | Citations (PDF) |
| 98 | Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD | 1.4 | 37 | Citations (PDF) |
| 99 | Clonal Hematopoiesis Is Associated With Higher Risk of Stroke | 5.9 | 208 | Citations (PDF) |
| 100 | Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk | 2.2 | 193 | Citations (PDF) |
| 101 | Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification | 2.0 | 31 | Citations (PDF) |
| 102 | Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease | 2.8 | 11 | Citations (PDF) |
| 103 | NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study | 2.4 | 5 | Citations (PDF) |
| 104 | Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT | 2.3 | 16 | Citations (PDF) |
| 105 | Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs | 6.2 | 125 | Citations (PDF) |
| 106 | Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes | 6.5 | 36 | Citations (PDF) |
| 107 | Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV | 3.4 | 63 | Citations (PDF) |
| 108 | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases | 2.4 | 57 | Citations (PDF) |
| 109 | Heart Failure Risk Associated With Severity of Modifiable Heart Failure Risk Factors: The ARIC Study | 4.0 | 15 | Citations (PDF) |
| 110 | Long-Term Effectiveness of the TIME Intervention to Improve Diabetes Outcomes in Low-Income Settings: a 2-Year Follow-Up | 2.4 | 17 | Citations (PDF) |
| 111 | Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment | 6.6 | 26 | Citations (PDF) |
| 112 | Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI | 4.0 | 40 | Citations (PDF) |
| 113 | Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study | 7.5 | 24 | Citations (PDF) |
| 114 | Associations of High‐Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT | 4.0 | 5 | Citations (PDF) |
| 115 | A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study | 4.0 | 9 | Citations (PDF) |
| 116 | Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials | 3.1 | 35 | Citations (PDF) |
| 117 | Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT | 4.0 | 26 | Citations (PDF) |
| 118 | Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential | 10.9 | 86 | Citations (PDF) |
| 119 | A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk | 12.5 | 84 | Citations (PDF) |
| 120 | Sex and Race Differences in N-Terminal Pro–B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community | 11.1 | 44 | Citations (PDF) |
| 121 | APOL1 Kidney Risk Variants and Proteomics | 4.2 | 11 | Citations (PDF) |
| 122 | Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study) | 1.8 | 45 | Citations (PDF) |
| 123 | Obesity, Galectin‐3, and Incident Heart Failure: The ARIC Study | 4.0 | 28 | Citations (PDF) |
| 124 | Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction | 2.3 | 53 | Citations (PDF) |
| 125 | Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study | 1.5 | 4 | Citations (PDF) |
| 126 | Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study | 6.6 | 59 | Citations (PDF) |
| 127 | Existing and emerging strategies to lower Lipoprotein(a) | 1.5 | 60 | Citations (PDF) |
| 128 | Lipoprotein(a) and ethnicities | 1.5 | 111 | Citations (PDF) |
| 129 | Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease | 1.3 | 10 | Citations (PDF) |
| 130 | Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr−/− Mice | 4.6 | 10 | Citations (PDF) |
| 131 | Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study | 4.0 | 43 | Citations (PDF) |
| 132 | Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia | 3.1 | 48 | Citations (PDF) |
| 133 | Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study | 1.1 | 14 | Citations (PDF) |
| 134 | PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance | 4.0 | 28 | Citations (PDF) |
| 135 | Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC) | 1.1 | 15 | Citations (PDF) |
| 136 | Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid | 4.0 | 17 | Citations (PDF) |
| 137 | Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy | 18.0 | 123 | Citations (PDF) |
| 138 | Long-term changes in plasma proteomic profiles in premenopausal and postmenopausal Black and White women: the Atherosclerosis Risk in Communities study | 2.4 | 3 | Citations (PDF) |
| 139 | Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD) | 2.0 | 7 | Citations (PDF) |
| 140 | Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease | 13.7 | 89 | Citations (PDF) |
| 141 | Patient and Clinician Perceptions of Precision Cardiology Care: Findings From the HeartCare Study | 2.9 | 1 | Citations (PDF) |
| 142 | Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine—Brief Report | 6.0 | 33 | Citations (PDF) |
| 143 | Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study | 4.0 | 26 | Citations (PDF) |
| 144 | Programmable Bio-NanoChip Technology for the Diagnosis of Cardiovascular
Disease at the Point of Care | 1.5 | 14 | Citations (PDF) |
| 145 | Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events | 11.1 | 29 | Citations (PDF) |
| 146 | Relation of Magnetic Resonance Imaging Based Arterial Signal Enhancement to Markers of Peripheral Artery Disease | 1.8 | 7 | Citations (PDF) |
| 147 | Reduction in Revascularization With Icosapent Ethyl | 18.0 | 55 | Citations (PDF) |
| 148 | High‐Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults | 2.9 | 20 | Citations (PDF) |
| 149 | REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results | 4.0 | 25 | Citations (PDF) |
| 150 | New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation | 18.7 | 16 | Citations (PDF) |
| 151 | Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation | 1.1 | 276 | Citations (PDF) |
| 152 | Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events | 2.3 | 79 | Citations (PDF) |
| 153 | Deficiency of Stat1 in CD11c+ Cells Alters Adipose Tissue Inflammation and Improves Metabolic Dysfunctions in Mice Fed a High-Fat Diet | 4.2 | 18 | Citations (PDF) |
| 154 | Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19 | 6.2 | 60 | Citations (PDF) |
| 155 | Letter to the Editor:
Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018 | 1.5 | 1 | Citations (PDF) |
| 156 | Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7 | 2.1 | 3 | Citations (PDF) |
| 157 | Genome-wide association study of circulating interleukin 6 levels identifies novel loci | 2.9 | 55 | Citations (PDF) |
| 158 | Recreational substance use among patients with premature atherosclerotic cardiovascular diseaseHeart, 2021, 107, 650-656 | 3.9 | 68 | Citations (PDF) |
| 159 | Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease—Perspective from the Veterans Affair Healthcare System | 2.1 | 6 | Citations (PDF) |
| 160 | Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study | 1.1 | 33 | Citations (PDF) |
| 161 | Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH | 4.0 | 10 | Citations (PDF) |
| 162 | Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease | 6.0 | 43 | Citations (PDF) |
| 163 | Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality | 2.2 | 91 | Citations (PDF) |
| 164 | Ten things to know about ten cardiovascular disease risk factors | 2.8 | 234 | Citations (PDF) |
| 165 | Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance | 13.7 | 26 | Citations (PDF) |
| 166 | Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19 | 2.8 | 16 | Citations (PDF) |
| 167 | Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes | 4.4 | 105 | Citations (PDF) |
| 168 | How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management? | 4.7 | 20 | Citations (PDF) |
| 169 | Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices | 13.7 | 27 | Citations (PDF) |
| 170 | Role of Bempedoic Acid in Clinical Practice | 2.1 | 134 | Citations (PDF) |
| 171 | Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study) | 1.8 | 14 | Citations (PDF) |
| 172 | Health care costs associated with primary care physicians versus nurse practitioners and physician assistants | 1.1 | 8 | Citations (PDF) |
| 173 | High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study | 6.2 | 42 | Citations (PDF) |
| 174 | Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial | 21.7 | 221 | Citations (PDF) |
| 175 | Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis | 2.1 | 23 | Citations (PDF) |
| 176 | Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk | 14.5 | 198 | Citations (PDF) |
| 177 | CD11c participates in triggering acute graft‐versus‐host disease during bone marrow transplantation | 4.7 | 16 | Citations (PDF) |
| 178 | Six‐year changes in N‐terminal pro‐brain natriuretic peptide and changes in weight and risk of obesity | 4.0 | 2 | Citations (PDF) |
| 179 | The ARIC (Atherosclerosis Risk In Communities) Study | 2.3 | 527 | Citations (PDF) |
| 180 | Development and Validation of Machine Learning–Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis | 18.0 | 114 | Citations (PDF) |
| 181 | Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease | 11.1 | 60 | Citations (PDF) |
| 182 | Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH) | 3.1 | 11 | Citations (PDF) |
| 183 | Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life | 1.8 | 11 | Citations (PDF) |
| 184 | Association of Clonal Hematopoiesis With Incident Heart Failure | 2.3 | 215 | Citations (PDF) |
| 185 | Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? | 2.9 | 2 | Citations (PDF) |
| 186 | Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia | 2.0 | 6 | Citations (PDF) |
| 187 | Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study) | 1.8 | 6 | Citations (PDF) |
| 188 | Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk | 11.1 | 69 | Citations (PDF) |
| 189 | Proteins Associated with Risk of Kidney Function Decline in the General Population | 0.4 | 50 | Citations (PDF) |
| 190 | Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease | 2.0 | 28 | Citations (PDF) |
| 191 | Association between circulating Galectin-3 and arterial stiffness in older adults | 1.6 | 4 | Citations (PDF) |
| 192 | Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications | 4.2 | 29 | Citations (PDF) |
| 193 | What Do US Physicians and Patients Think About Lipid‐Lowering Therapy and Goals of Treatment? Results From the GOULD Registry | 4.0 | 18 | Citations (PDF) |
| 194 | Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis | 8.2 | 349 | Citations (PDF) |
| 195 | 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia | 2.3 | 291 | Citations (PDF) |
| 196 | Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US | 11.1 | 201 | Citations (PDF) |
| 197 | Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering | 11.1 | 61 | Citations (PDF) |
| 198 | Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy | 2.3 | 14 | Citations (PDF) |
| 199 | Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia | 4.0 | 19 | Citations (PDF) |
| 200 | Cardiovascular Disease Risk–Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network | 4.1 | 31 | Citations (PDF) |
| 201 | Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin | 13.7 | 26 | Citations (PDF) |
| 202 | Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group | 3.1 | 116 | Citations (PDF) |
| 203 | Polygenic Risk Scores for Kidney Function and Their Associations with Circulating Proteome, and Incident Kidney Diseases | 0.4 | 62 | Citations (PDF) |
| 204 | Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults | 3.2 | 16 | Citations (PDF) |
| 205 | High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study | 2.4 | 9 | Citations (PDF) |
| 206 | High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study | 1.1 | 8 | Citations (PDF) |
| 207 | Poststatin Lipid Therapeutics: A Review | 1.5 | 10 | Citations (PDF) |
| 208 | Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT | 2.3 | 35 | Citations (PDF) |
| 209 | Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system | 3.1 | 5 | Citations (PDF) |
| 210 | Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins | 2.8 | 20 | Citations (PDF) |
| 211 | Center for Cardiovascular Disease Prevention: Risk Assessment and
Reduction | 1.5 | 0 | Citations (PDF) |
| 212 | Regression of Atherosclerosis: Where are We Now, and Where are We
Going? | 1.5 | 0 | Citations (PDF) |
| 213 | Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG | 18.0 | 54 | Citations (PDF) |
| 214 | Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL | 18.0 | 66 | Citations (PDF) |
| 215 | Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond | 2.2 | 4 | Citations (PDF) |
| 216 | Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation | 2.9 | 15 | Citations (PDF) |
| 217 | The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community | 2.3 | 1 | Citations (PDF) |
| 218 | Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020? | 2.0 | 1 | Citations (PDF) |
| 219 | Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study) | 1.8 | 27 | Citations (PDF) |
| 220 | JCL Roundtable. Making prevention a priority | 3.1 | 3 | Citations (PDF) |
| 221 | Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male
Ldlr
–/–
Mice | 6.0 | 28 | Citations (PDF) |
| 222 | Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy | 2.0 | 329 | Citations (PDF) |
| 223 | Dietary and Pharmacological Fatty Acids and Cardiovascular Health | 4.0 | 52 | Citations (PDF) |
| 224 | REDUCE-IT USA | 18.0 | 127 | Citations (PDF) |
| 225 | Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States | 2.9 | 24 | Citations (PDF) |
| 226 | Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial | 2.9 | 8 | Citations (PDF) |
| 227 | Mortality Implications of Prediabetes and Diabetes in Older Adults | 6.2 | 81 | Citations (PDF) |
| 228 | Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women | 4.0 | 35 | Citations (PDF) |
| 229 | Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials | 3.1 | 95 | Citations (PDF) |
| 230 | Monocyte phenotyping and management of lipoprotein X syndrome | 3.1 | 6 | Citations (PDF) |
| 231 | Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk | 16.5 | 926 | Citations (PDF) |
| 232 | Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk | 2.3 | 91 | Citations (PDF) |
| 233 | Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study | 4.0 | 62 | Citations (PDF) |
| 234 | Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis | 11.1 | 26 | Citations (PDF) |
| 235 | Combining Biomarkers and Imaging for Short‐Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults | 4.0 | 30 | Citations (PDF) |
| 236 | Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease | 6.0 | 51 | Citations (PDF) |
| 237 | Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018 | 2.0 | 36 | Citations (PDF) |
| 238 | High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes | 6.2 | 16 | Citations (PDF) |
| 239 | Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD | 2.1 | 28 | Citations (PDF) |
| 240 | Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease | 6.6 | 45 | Citations (PDF) |
| 241 | Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin‐Associated Side Effects | 4.0 | 30 | Citations (PDF) |
| 242 | C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV | 2.8 | 5 | Citations (PDF) |
| 243 | Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction | 2.0 | 51 | Citations (PDF) |
| 244 | Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men | 1.9 | 10 | Citations (PDF) |
| 245 | Physical Activity and Incident Heart Failure in High‐Risk Subgroups: The ARIC Study | 4.0 | 18 | Citations (PDF) |
| 246 | Metabolic Inflammation and Insulin Resistance in Obesity | 13.1 | 947 | Citations (PDF) |
| 247 | Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study | 1.3 | 8 | Citations (PDF) |
| 248 | Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions | 4.7 | 57 | Citations (PDF) |
| 249 | Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity | 18.0 | 73 | Citations (PDF) |
| 250 | JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes | 3.1 | 5 | Citations (PDF) |
| 251 | Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes | 6.2 | 36 | Citations (PDF) |
| 252 | Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study | 4.0 | 7 | Citations (PDF) |
| 253 | Levels and Change in Galectin‐3 and Association With Cardiovascular Events: The ARIC Study | 4.0 | 29 | Citations (PDF) |
| 254 | Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor | 0.5 | 4 | Citations (PDF) |
| 255 | Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry | 2.0 | 31 | Citations (PDF) |
| 256 | Facility-Level Variation in Cardiac Stress Test Use Among Patients With Diabetes: Findings From the Veterans Affairs National Database | 6.2 | 3 | Citations (PDF) |
| 257 | The Use of Sex-Specific Factors in the Assessment of Women’s Cardiovascular Risk | 18.0 | 186 | Citations (PDF) |
| 258 | Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure | 18.0 | 49 | Citations (PDF) |
| 259 | Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes | 16.5 | 156 | Citations (PDF) |
| 260 | Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System) | 1.8 | 24 | Citations (PDF) |
| 261 | Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease | 6.2 | 33 | Citations (PDF) |
| 262 | Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB? | 2.2 | 5 | Citations (PDF) |
| 263 | Associations of Cardiac, Kidney, and Diabetes Biomarkers With Peripheral Neuropathy among Older Adults in the Atherosclerosis Risk in Communities (ARIC) Study | 1.1 | 17 | Citations (PDF) |
| 264 | Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System | 2.1 | 1 | Citations (PDF) |
| 265 | Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective | 2.1 | 15 | Citations (PDF) |
| 266 | Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study | 1.9 | 25 | Citations (PDF) |
| 267 | Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides | 2.5 | 8 | Citations (PDF) |
| 268 | Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study) | 1.8 | 45 | Citations (PDF) |
| 269 | Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study | 2.9 | 26 | Citations (PDF) |
| 270 | High‐Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change | 2.9 | 12 | Citations (PDF) |
| 271 | Preventive Cardiology as a Subspecialty of Cardiovascular Medicine | 2.3 | 51 | Citations (PDF) |
| 272 | Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline | 18.0 | 80 | Citations (PDF) |
| 273 | Statin use in carnitine palmitoyltransferase II deficiency | 3.1 | 2 | Citations (PDF) |
| 274 | Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration | 13.7 | 86 | Citations (PDF) |
| 275 | Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults | 11.1 | 59 | Citations (PDF) |
| 276 | Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke | 13.1 | 107 | Citations (PDF) |
| 277 | Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction | 2.9 | 6 | Citations (PDF) |
| 278 | Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions | 3.3 | 114 | Citations (PDF) |
| 279 | The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines | 1.7 | 25 | Citations (PDF) |
| 280 | Homozygous Familial Hypercholesterolemia in the United States: Data from the CASCADE-FH Registry† | 3.1 | 0 | Citations (PDF) |
| 281 | Genetic Testing for Hypertriglyceridemia - Pilot Data from a Single Center Lipid Clinic | 3.1 | 0 | Citations (PDF) |
| 282 | Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease | 18.0 | 118 | Citations (PDF) |
| 283 | Effects of Icosapent Ethyl on Total Ischemic Events | 2.3 | 246 | Citations (PDF) |
| 284 | Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study | 3.3 | 4 | Citations (PDF) |
| 285 | Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System | 2.0 | 39 | Citations (PDF) |
| 286 | Letter by Wu and Ballantyne Regarding Article, “Protein Kinase Cθ via Activating Transcription Factor 2–Mediated CD36 Expression and Foam Cell Formation of Ly6C
<sup>hi</sup>
Cells Contributes to Atherosclerosis” | 18.0 | 0 | Citations (PDF) |
| 287 | Metabolomic Pattern Predicts Incident Coronary Heart Disease | 6.0 | 96 | Citations (PDF) |
| 288 | Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study) | 1.8 | 19 | Citations (PDF) |
| 289 | Subsequent Event Risk in Individuals With Established Coronary Heart Disease | 2.9 | 19 | Citations (PDF) |
| 290 | Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events | 2.9 | 30 | Citations (PDF) |
| 291 | ApoB, small-dense LDL-C, Lp(a), LpPLA
2
activity, and cognitive change | 1.0 | 32 | Citations (PDF) |
| 292 | High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study | 18.0 | 205 | Citations (PDF) |
| 293 | Understanding by General Providers of the Echocardiogram Report | 1.8 | 2 | Citations (PDF) |
| 294 | Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial | 18.0 | 20 | Citations (PDF) |
| 295 | Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults | 2.3 | 21 | Citations (PDF) |
| 296 | Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay | 1.3 | 111 | Citations (PDF) |
| 297 | Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol | 34.5 | 741 | Citations (PDF) |
| 298 | Multi-ancestry genome-wide gene–smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids | 25.2 | 136 | Citations (PDF) |
| 299 | Cancer Survivorship and Subclinical Myocardial Damage | 3.3 | 11 | Citations (PDF) |
| 300 | Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study | 2.3 | 20 | Citations (PDF) |
| 301 | Sleep apnea and galectin-3: possible sex-specific relationship | 1.5 | 15 | Citations (PDF) |
| 302 | The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs | 3.1 | 27 | Citations (PDF) |
| 303 | Response by Jia et al to Letter Regarding Article, “High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study” | 18.0 | 3 | Citations (PDF) |
| 304 | Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes | 3.4 | 18 | Citations (PDF) |
| 305 | Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis | 2.9 | 97 | Citations (PDF) |
| 306 | Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans | 11.1 | 50 | Citations (PDF) |
| 307 | Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial | 18.0 | 12 | Citations (PDF) |
| 308 | Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia | 34.5 | 3,025 | Citations (PDF) |
| 309 | Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia | 1.5 | 54 | Citations (PDF) |
| 310 | Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease | 4.1 | 4 | Citations (PDF) |
| 311 | Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study | 1.5 | 70 | Citations (PDF) |
| 312 | Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol | 2.5 | 10 | Citations (PDF) |
| 313 | Bempedoic Acid (ETC-1002) | 1.5 | 45 | Citations (PDF) |
| 314 | Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs | 2.4 | 53 | Citations (PDF) |
| 315 | Low Density Lipoprotein Triglyceride and Incident Cardiovascular: Insights from the Atherosclerosis Risk in Communities Study* | 3.1 | 0 | Citations (PDF) |
| 316 | Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study) | 1.8 | 10 | Citations (PDF) |
| 317 | Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure | 18.0 | 54 | Citations (PDF) |
| 318 | Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials) | 1.8 | 22 | Citations (PDF) |
| 319 | Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study | 11.1 | 56 | Citations (PDF) |
| 320 | Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study) | 1.8 | 17 | Citations (PDF) |
| 321 | SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study | 3.2 | 18 | Citations (PDF) |
| 322 | Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts | 2.9 | 7 | Citations (PDF) |
| 323 | Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study | 1.5 | 30 | Citations (PDF) |
| 324 | The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study | 3.4 | 77 | Citations (PDF) |
| 325 | Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults | 2.3 | 83 | Citations (PDF) |
| 326 | Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis | 2.1 | 13 | Citations (PDF) |
| 327 | High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study | 2.2 | 57 | Citations (PDF) |
| 328 | Patient-specific flow descriptors and normalised wall index in peripheral artery disease: a preliminary study | 1.1 | 10 | Citations (PDF) |
| 329 | Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care | 1.5 | 35 | Citations (PDF) |
| 330 | Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease | 5.3 | 74 | Citations (PDF) |
| 331 | Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC) | 1.5 | 15 | Citations (PDF) |
| 332 | Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study | 1.5 | 42 | Citations (PDF) |
| 333 | Weight History and Subclinical Myocardial Damage | 1.1 | 21 | Citations (PDF) |
| 334 | Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial | 62.1 | 841 | Citations (PDF) |
| 335 | Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD | 4.2 | 29 | Citations (PDF) |
| 336 | Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study | 4.1 | 25 | Citations (PDF) |
| 337 | Effect of Evolocumab on Coronary Plaque Composition | 2.3 | 133 | Citations (PDF) |
| 338 | Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders | 6.5 | 427 | Citations (PDF) |
| 339 | Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study | 1.1 | 4 | Citations (PDF) |
| 340 | Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions | 4.7 | 14 | Citations (PDF) |
| 341 | Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease | 2.3 | 169 | Citations (PDF) |
| 342 | Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse | 3.1 | 11 | Citations (PDF) |
| 343 | Clinical Genetic Testing for Familial Hypercholesterolemia | 2.3 | 569 | Citations (PDF) |
| 344 | Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial | 11.1 | 163 | Citations (PDF) |
| 345 | Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism | 3.8 | 13 | Citations (PDF) |
| 346 | Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL | 4.1 | 51 | Citations (PDF) |
| 347 | Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle‐Aged Adults | 4.0 | 82 | Citations (PDF) |
| 348 | Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) | 2.2 | 534 | Citations (PDF) |
| 349 | Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial | 2.0 | 161 | Citations (PDF) |
| 350 | Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study | 1.5 | 387 | Citations (PDF) |
| 351 | Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the Metabochip in the Population Architecture using Genomics and Epidemiology (PAGE) study | 2.9 | 21 | Citations (PDF) |
| 352 | Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity | 7.5 | 103 | Citations (PDF) |
| 353 | Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry | 4.0 | 32 | Citations (PDF) |
| 354 | Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease | 0.5 | 15 | Citations (PDF) |
| 355 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure | 4.0 | 2 | Citations (PDF) |
| 356 | Myocardial Injury, Obesity, and the Obesity Paradox | 4.4 | 22 | Citations (PDF) |
| 357 | Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials) | 1.8 | 16 | Citations (PDF) |
| 358 | Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study | 2.7 | 33 | Citations (PDF) |
| 359 | Practical Approaches for Whole-Genome Sequence Analysis of Heart- and Blood-Related Traits | 6.5 | 56 | Citations (PDF) |
| 360 | Assessing Cardiovascular Risk and Testing in Type 2 Diabetes | 2.9 | 20 | Citations (PDF) |
| 361 | Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study | 5.3 | 16 | Citations (PDF) |
| 362 | Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study | 2.0 | 20 | Citations (PDF) |
| 363 | Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide | 11.1 | 100 | Citations (PDF) |
| 364 | BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study | 2.2 | 51 | Citations (PDF) |
| 365 | Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARγ | 13.7 | 67 | Citations (PDF) |
| 366 | Physical Activity, Obesity, and Subclinical Myocardial Damage | 4.4 | 25 | Citations (PDF) |
| 367 | Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial | 1.5 | 43 | Citations (PDF) |
| 368 | A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol | 1.8 | 16 | Citations (PDF) |
| 369 | Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) | 18.0 | 62 | Citations (PDF) |
| 370 | Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease | 18.0 | 36 | Citations (PDF) |
| 371 | Lipoprotein (a) levels and Risk of Cardiovascular Disease Events in Diabetes Mellitus and Prediabetes: The Atherosclerosis Risk in Communities Study | 3.1 | 0 | Citations (PDF) |
| 372 | Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative | 2.2 | 38 | Citations (PDF) |
| 373 | Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study | 21.7 | 104 | Citations (PDF) |
| 374 | The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study | 1.5 | 55 | Citations (PDF) |
| 375 | An
NPPB
Promoter Polymorphism Associated With Elevated N‐Terminal pro–B‐Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality | 4.0 | 53 | Citations (PDF) |
| 376 | DEVELOPMENT AND VALIDATION OF PREDICTION MODELS WITH NON-TRADITIONAL MARKERS FOR 10-YEAR RISK OF ISCHEMIC LEG AMPUTATION AMONG PERSONS WITH DIABETES: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY | 2.3 | 0 | Citations (PDF) |
| 377 | Multimodality Strategy for Cardiovascular Risk Assessment | 18.0 | 107 | Citations (PDF) |
| 378 | Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial | 2.0 | 177 | Citations (PDF) |
| 379 | High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study | 6.2 | 25 | Citations (PDF) |
| 380 | Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry | 1.5 | 91 | Citations (PDF) |
| 381 | Exome-wide association study of plasma lipids in >300,000 individuals | 25.2 | 552 | Citations (PDF) |
| 382 | Midlife systemic inflammatory markers are associated with late-life brain volume | 1.0 | 142 | Citations (PDF) |
| 383 | Sedentary Behavior and Subclinical Cardiac Injury | 18.0 | 10 | Citations (PDF) |
| 384 | Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial | 62.1 | 1,265 | Citations (PDF) |
| 385 | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | 34.5 | 8,752 | Citations (PDF) |
| 386 | 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk | 2.3 | 349 | Citations (PDF) |
| 387 | Association of Elevated Triglycerides and Atherogenic Lipoproteins with Incident Cardiovascular Diseases: Insights from Genetic Data in the Atherosclerosis Risk in Communities Study | 3.1 | 3 | Citations (PDF) |
| 388 | Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study | 2.9 | 47 | Citations (PDF) |
| 389 | Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study | 4.0 | 15 | Citations (PDF) |
| 390 | Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study | 4.0 | 69 | Citations (PDF) |
| 391 | Galectin‐3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study | 0.5 | 18 | Citations (PDF) |
| 392 | Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease | 5.9 | 114 | Citations (PDF) |
| 393 | Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN | 1.5 | 43 | Citations (PDF) |
| 394 | Pediatric Familial Hypercholesterolemia: Children and Adolescents Enrolled in the CAscade SCreening for Awareness | 3.1 | 3 | Citations (PDF) |
| 395 | Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol | 1.8 | 15 | Citations (PDF) |
| 396 | Evaluation of the efficacy, safety and glycaemic effects of evolocumab (
AMG
145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome | 4.5 | 64 | Citations (PDF) |
| 397 | Skeletal muscle inflammation and insulin resistance in obesity | 10.6 | 648 | Citations (PDF) |
| 398 | Influence of Cigarette Smoking on Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study | 7.3 | 44 | Citations (PDF) |
| 399 | Galectin‐3 and Risk of Heart Failure and Death in Blacks and Whites | 4.0 | 28 | Citations (PDF) |
| 400 | Meta-analysis of genome-wide association studies of HDL cholesterol response to statins | 3.8 | 35 | Citations (PDF) |
| 401 | 25‐Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study | 4.0 | 11 | Citations (PDF) |
| 402 | P2‐415: Association of Baseline Lipids with 20‐Year Cognitive Change: The ARIC Neurocognitive Study | 0.5 | 0 | Citations (PDF) |
| 403 | Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV) | 2.9 | 50 | Citations (PDF) |
| 404 | Provider understanding of the 2013 ACC/AHA cholesterol guideline | 3.1 | 65 | Citations (PDF) |
| 405 | Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids | 3.1 | 1 | Citations (PDF) |
| 406 | Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance | 16.5 | 496 | Citations (PDF) |
| 407 | 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk | 2.3 | 396 | Citations (PDF) |
| 408 | Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population | 2.3 | 286 | Citations (PDF) |
| 409 | Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events | 2.3 | 334 | Citations (PDF) |
| 410 | Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis | 21.7 | 203 | Citations (PDF) |
| 411 | Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act | 2.9 | 65 | Citations (PDF) |
| 412 | Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies | 1.5 | 49 | Citations (PDF) |
| 413 | Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease | 1.8 | 49 | Citations (PDF) |
| 414 | On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) | 2.9 | 16 | Citations (PDF) |
| 415 | Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase | 4.7 | 110 | Citations (PDF) |
| 416 | Statin Use and Its Facility‐Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database | 2.0 | 45 | Citations (PDF) |
| 417 | Postprandial Monocyte Activation in Individuals With Metabolic Syndrome | 4.0 | 52 | Citations (PDF) |
| 418 | US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry | 3.1 | 70 | Citations (PDF) |
| 419 | Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study | 1.1 | 18 | Citations (PDF) |
| 420 | Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study | 1.5 | 19 | Citations (PDF) |
| 421 | Obesity and Subtypes of Incident Cardiovascular Disease | 4.0 | 231 | Citations (PDF) |
| 422 | Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies | 2.2 | 40 | Citations (PDF) |
| 423 | Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients | 16.5 | 1,100 | Citations (PDF) |
| 424 | Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death | 11.1 | 135 | Citations (PDF) |
| 425 | The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study | 2.0 | 5 | Citations (PDF) |
| 426 | Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy | 1.8 | 107 | Citations (PDF) |
| 427 | Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies | 3.1 | 35 | Citations (PDF) |
| 428 | Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition | 3.8 | 7 | Citations (PDF) |
| 429 | Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance | 3.1 | 133 | Citations (PDF) |
| 430 | Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States | 3.8 | 200 | Citations (PDF) |
| 431 | Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial | 2.0 | 37 | Citations (PDF) |
| 432 | Genetic Testing in Hyperlipidemia | 3.5 | 5 | Citations (PDF) |
| 433 | The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study | 3.3 | 39 | Citations (PDF) |
| 434 | Cardiac ScoreCard: A diagnostic multivariate index assay system for predicting a spectrum of cardiovascular disease | 7.3 | 37 | Citations (PDF) |
| 435 | Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline | 1.5 | 20 | Citations (PDF) |
| 436 | Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease | 2.3 | 19 | Citations (PDF) |
| 437 | Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population | 1.8 | 29 | Citations (PDF) |
| 438 | N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity | 18.0 | 118 | Citations (PDF) |
| 439 | Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study | 6.2 | 60 | Citations (PDF) |
| 440 | Abstract 12141: ApoE-HDL Cholesterol Predicts Incident Cardiovascular Events: Aric Study | 18.0 | 2 | Citations (PDF) |
| 441 | A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease | 10.6 | 31 | Citations (PDF) |
| 442 | Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study | 2.3 | 66 | Citations (PDF) |
| 443 | Pharmacokinetic and Triglyceride-lowering Pharmacodynamic Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Across Clinical Studies† | 3.1 | 1 | Citations (PDF) |
| 444 | Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T | 4.2 | 2 | Citations (PDF) |
| 445 | Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk | 3.8 | 13 | Citations (PDF) |
| 446 | Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality | 2.9 | 103 | Citations (PDF) |
| 447 | Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD | 6.2 | 32 | Citations (PDF) |
| 448 | Genetic Testing in Hyperlipidemia | 1.5 | 8 | Citations (PDF) |
| 449 | Racial Differences in Circulating Natriuretic Peptide Levels: The Atherosclerosis Risk in Communities Study | 4.0 | 67 | Citations (PDF) |
| 450 | Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study | 2.9 | 41 | Citations (PDF) |
| 451 | Lipoprotein‐associated phospholipase A2, homocysteine, and Alzheimer's disease | 2.4 | 32 | Citations (PDF) |
| 452 | Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study | 0.8 | 38 | Citations (PDF) |
| 453 | sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study | 2.4 | 25 | Citations (PDF) |
| 454 | Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study | 1.4 | 23 | Citations (PDF) |
| 455 | Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease | 2.3 | 70 | Citations (PDF) |
| 456 | Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study | 4.6 | 135 | Citations (PDF) |
| 457 | Plasma Lactate and Incident Hypertension in the Atherosclerosis Risk in Communities Study | 2.0 | 56 | Citations (PDF) |
| 458 | Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry*† | 3.1 | 0 | Citations (PDF) |
| 459 | Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study | 1.5 | 17 | Citations (PDF) |
| 460 | Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence | 18.0 | 112 | Citations (PDF) |
| 461 | Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance | 3.0 | 166 | Citations (PDF) |
| 462 | High-Sensitivity Cardiac Troponin T and Risk of Hypertension | 18.0 | 98 | Citations (PDF) |
| 463 | A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes | 2.4 | 12 | Citations (PDF) |
| 464 | Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults | 6.6 | 12 | Citations (PDF) |
| 465 | Foamy Monocytes Form Early and Contribute to Nascent Atherosclerosis in Mice With Hypercholesterolemia | 6.0 | 83 | Citations (PDF) |
| 466 | Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria | 2.0 | 10 | Citations (PDF) |
| 467 | Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia | 1.8 | 161 | Citations (PDF) |
| 468 | The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial | 1.5 | 73 | Citations (PDF) |
| 469 | The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia | 4.7 | 0 | Citations (PDF) |
| 470 | Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events | 34.5 | 1,489 | Citations (PDF) |
| 471 | Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study | 2.2 | 41 | Citations (PDF) |
| 472 | Eligibility for Statin Therapy According to New Cholesterol Guidelines and Prevalent Use of Medication to Lower Lipid Levels in an Older US Cohort | 10.6 | 22 | Citations (PDF) |
| 473 | Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts | 1.8 | 16 | Citations (PDF) |
| 474 | Recalibration of Blood Analytes over 25 Years in the Atherosclerosis Risk in Communities Study: Impact of Recalibration on Chronic Kidney Disease Prevalence and Incidence | 1.1 | 81 | Citations (PDF) |
| 475 | N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study | 2.0 | 37 | Citations (PDF) |
| 476 | Postprandial effects on arterial stiffness parameters in healthy young adults | 2.4 | 10 | Citations (PDF) |
| 477 | Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort | 18.0 | 175 | Citations (PDF) |
| 478 | Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome | 1.9 | 21 | Citations (PDF) |
| 479 | Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly | 18.0 | 69 | Citations (PDF) |
| 480 | Validity of self-report of lipid medication use: The Atherosclerosis Risk in Communities (ARIC) Study | 1.5 | 8 | Citations (PDF) |
| 481 | Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis | 1.1 | 41 | Citations (PDF) |
| 482 | Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study) | 3.1 | 41 | Citations (PDF) |
| 483 | Provider Type and Quality of Outpatient Cardiovascular Disease Care | 2.3 | 59 | Citations (PDF) |
| 484 | The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease | 4.2 | 47 | Citations (PDF) |
| 485 | High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories | 6.6 | 42 | Citations (PDF) |
| 486 | Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease | 1.8 | 167 | Citations (PDF) |
| 487 | Development of Chagas Cardiac Manifestations Among Texas Blood Donors | 1.8 | 33 | Citations (PDF) |
| 488 | High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study | 2.9 | 67 | Citations (PDF) |
| 489 | Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial | 2.5 | 95 | Citations (PDF) |
| 490 | Analysis of Multiple Association Studies Provides Evidence of an Expression QTL Hub in Gene-Gene Interaction Network Affecting HDL Cholesterol Levels | 2.3 | 11 | Citations (PDF) |
| 491 | Low-Density Lipoprotein Electronegativity Is a Novel Cardiometabolic Risk Factor | 2.3 | 26 | Citations (PDF) |
| 492 | Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins | 13.7 | 253 | Citations (PDF) |
| 493 | High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study | 2.2 | 56 | Citations (PDF) |
| 494 | Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial | 2.2 | 236 | Citations (PDF) |
| 495 | Neck Circumference Is Not Associated With Subclinical Atherosclerosis in Retired National Football League Players | 2.0 | 21 | Citations (PDF) |
| 496 | Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players | 1.8 | 14 | Citations (PDF) |
| 497 | B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies | 2.0 | 166 | Citations (PDF) |
| 498 | Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies | 3.3 | 54 | Citations (PDF) |
| 499 | Pre-Morbid Body Mass Index and Mortality After Incident Heart Failure | 2.3 | 92 | Citations (PDF) |
| 500 | Essential Role of CD11a in CD8
+
T-Cell Accumulation and Activation in Adipose Tissue | 6.0 | 65 | Citations (PDF) |
| 501 | Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study | 2.0 | 20 | Citations (PDF) |
| 502 | Distribution of calcification in carotid endarterectomy tissues: Comparison of micro-computed tomography imaging with histology | 2.4 | 11 | Citations (PDF) |
| 503 | Troponin T, NT-proBNP, and venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) | 2.4 | 19 | Citations (PDF) |
| 504 | Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study | 1.5 | 44 | Citations (PDF) |
| 505 | Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies | 3.1 | 8 | Citations (PDF) |
| 506 | Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia | 1.5 | 12 | Citations (PDF) |
| 507 | Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE) | 1.8 | 18 | Citations (PDF) |
| 508 | ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure | 3.1 | 0 | Citations (PDF) |
| 509 | Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency | 1.5 | 95 | Citations (PDF) |
| 510 | Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol | 6.5 | 207 | Citations (PDF) |
| 511 | A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia | 34.5 | 688 | Citations (PDF) |
| 512 | The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 | 2.2 | 285 | Citations (PDF) |
| 513 | Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN | 1.4 | 159 | Citations (PDF) |
| 514 | Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry | 2.9 | 78 | Citations (PDF) |
| 515 | Obesity, Subclinical Myocardial Injury, and Incident Heart Failure | 4.4 | 103 | Citations (PDF) |
| 516 | Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease | 34.5 | 412 | Citations (PDF) |
| 517 | Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease | 6.0 | 473 | Citations (PDF) |
| 518 | Lipid lowering with PCSK9 inhibitors | 35.5 | 233 | Citations (PDF) |
| 519 | Review of Clinical Practice Guidelines for the Management of LDL-Related Risk | 2.3 | 59 | Citations (PDF) |
| 520 | Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage | 18.0 | 194 | Citations (PDF) |
| 521 | Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players | 1.5 | 8 | Citations (PDF) |
| 522 | High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN | 6.2 | 56 | Citations (PDF) |
| 523 | Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy | 6.1 | 56 | Citations (PDF) |
| 524 | Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome | 6.0 | 48 | Citations (PDF) |
| 525 | Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans | 2.9 | 36 | Citations (PDF) |
| 526 | Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study | 2.9 | 18 | Citations (PDF) |
| 527 | Cardiac and Kidney Markers for Cardiovascular Prediction in Individuals With Chronic Kidney Disease | 6.0 | 72 | Citations (PDF) |
| 528 | ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies | 3.1 | 3 | Citations (PDF) |
| 529 | Association Between Low Density Lipoprotein Cholesterol or Low Density Lipoprotein Particle Concentration and Metabolic Syndrome and High Sensitivity C-Reactive Protein in Retired National Football League Players* | 3.1 | 0 | Citations (PDF) |
| 530 | Fiber Intake and Plasminogen Activator Inhibitor-1 in Type 2 Diabetes: Look AHEAD (Action for Health in Diabetes) Trial Findings at Baseline and Year 1 | 1.5 | 11 | Citations (PDF) |
| 531 | Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy | 6.0 | 61 | Citations (PDF) |
| 532 | Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay | 2.3 | 346 | Citations (PDF) |
| 533 | Lipoprotein Associated Phospholipase A2 Mass is Not Associated with Subclinical Coronary and Carotid Atherosclerosis in the Retired National Football League Players* | 3.1 | 0 | Citations (PDF) |
| 534 | Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock | 2.2 | 18 | Citations (PDF) |
| 535 | Association of Small Dense Low-Density Lipoprotein Cholesterol and Lipoprotein-Associated Phospholipase A2 with Carotid Plaque Characteristics in the Atherosclerosis Risk in Communities Study* | 3.1 | 0 | Citations (PDF) |
| 536 | Loss-of-Function Mutations inAPOC3,Triglycerides, and Coronary Disease | 34.5 | 1,088 | Citations (PDF) |
| 537 | Is High‐Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low‐ to Moderate‐Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines | 2.0 | 62 | Citations (PDF) |
| 538 | The Challenges of Genome-Wide Interaction Studies: Lessons to Learn from the Analysis of HDL Blood Levels | 2.3 | 14 | Citations (PDF) |
| 539 | Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players | 0.5 | 19 | Citations (PDF) |
| 540 | Chronic inflammation role in the obesity-diabetes association: a case-cohort study | 3.4 | 93 | Citations (PDF) |
| 541 | Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies | 2.5 | 134 | Citations (PDF) |
| 542 | A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease | 3.1 | 23 | Citations (PDF) |
| 543 | Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality | 1.7 | 83 | Citations (PDF) |
| 544 | The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT) | 1.5 | 34 | Citations (PDF) |
| 545 | Comparison by Meta-Analysis of Mortality After Isolated Coronary Artery Bypass Grafting in Women Versus Men | 1.8 | 120 | Citations (PDF) |
| 546 | Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis | 2.2 | 69 | Citations (PDF) |
| 547 | Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial) | 1.8 | 27 | Citations (PDF) |
| 548 | New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs | 2.2 | 95 | Citations (PDF) |
| 549 | Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome | 2.2 | 60 | Citations (PDF) |
| 550 | Troponin T and N-Terminal Pro–B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk—The Atherosclerosis Risk in Communities Study | 1.1 | 101 | Citations (PDF) |
| 551 | Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study | 9.4 | 66 | Citations (PDF) |
| 552 | Troponin T, N-Terminal Pro–B-Type Natriuretic Peptide, and Incidence of Stroke | 5.9 | 166 | Citations (PDF) |
| 553 | RESULTS FROM THE FENOFIBRIC ACID ON CAROTID INTIMA-MEDIA THICKNESS IN SUBJECTS WITH TYPE IIB DYSLIPIDEMIA WITH RESIDUAL RISK IN ADDITION TO ATORVASTATIN THERAPY (FIRST) TRIAL | 2.3 | 2 | Citations (PDF) |
| 554 | Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study | 2.3 | 2 | Citations (PDF) |
| 555 | Response to Zhou et al. “Letter to the Editor: The effects of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample” | 5.8 | 0 | Citations (PDF) |
| 556 | Single Nucleotide Polymorphisms in Cholesteryl Ester Transfer Protein Gene and Recurrent Coronary Heart Disease or Mortality in Patients With Established Atherosclerosis | 1.8 | 6 | Citations (PDF) |
| 557 | Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome | 3.1 | 16 | Citations (PDF) |
| 558 | The Editor's Roundtable: Hypertriglyceridemia | 1.8 | 2 | Citations (PDF) |
| 559 | Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome | 3.1 | 20 | Citations (PDF) |
| 560 | Application of Speckle-Tracking in the Evaluation of Carotid Artery Function in Subjects with Hypertension and Diabetes | 3.4 | 17 | Citations (PDF) |
| 561 | ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects† | 3.1 | 0 | Citations (PDF) |
| 562 | Association between statins and infections after coronary artery bypass grafting | 2.2 | 19 | Citations (PDF) |
| 563 | Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia | 2.3 | 164 | Citations (PDF) |
| 564 | sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death | 4.2 | 160 | Citations (PDF) |
| 565 | CD11a Regulates Effector CD8 T Cell Differentiation and Central Memory Development in Response to Infection with Listeria monocytogenes | 2.7 | 47 | Citations (PDF) |
| 566 | Factors underlying regression of coronary atheroma with potent statin therapy | 2.2 | 73 | Citations (PDF) |
| 567 | Cardiovascular Biomarkers and Subclinical Brain Disease in the Atherosclerosis Risk in Communities Study | 5.9 | 73 | Citations (PDF) |
| 568 | Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy | 2.2 | 94 | Citations (PDF) |
| 569 | Sleep Apnea Is Associated with Subclinical Myocardial Injury in the Community. The ARIC-SHHS Study | 8.9 | 82 | Citations (PDF) |
| 570 | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy | 3.6 | 9 | Citations (PDF) |
| 571 | Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained | 3.2 | 115 | Citations (PDF) |
| 572 | Elevated High-Sensitivity C-Reactive Protein as a Risk Marker of the Attenuated Relationship Between Serum Cholesterol and Cardiovascular Events at Older Age | 3.3 | 35 | Citations (PDF) |
| 573 | Association of Genome-Wide Variation With Highly Sensitive Cardiac Troponin-T Levels in European Americans and Blacks | 3.8 | 25 | Citations (PDF) |
| 574 | Combined Association of Creatinine, Albuminuria, and Cystatin C with All-Cause Mortality and Cardiovascular and Kidney Outcomes | 4.2 | 37 | Citations (PDF) |
| 575 | Novel Risk Factors and the Prediction of Type 2 Diabetes in the Atherosclerosis Risk in Communities (ARIC) Study | 6.2 | 42 | Citations (PDF) |
| 576 | The Association of Plasma Lactate With Incident Cardiovascular Outcomes | 3.3 | 41 | Citations (PDF) |
| 577 | NH2-Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes | 4.2 | 93 | Citations (PDF) |
| 578 | Do Genetic Modifiers of High-Density Lipoprotein Cholesterol and Triglyceride Levels Also Modify Their Response to a Lifestyle Intervention in the Setting of Obesity and Type-2 Diabetes Mellitus? | 3.8 | 30 | Citations (PDF) |
| 579 | Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study | 4.0 | 54 | Citations (PDF) |
| 580 | Association Between Preoperative Diuretic Use and In‐hospital Outcomes After Cardiac Surgery | 5.3 | 13 | Citations (PDF) |
| 581 | Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes | 4.2 | 122 | Citations (PDF) |
| 582 | APOEModulates the Correlation Between Triglycerides, Cholesterol, and CHD Through Pleiotropy, and Gene-by-Gene Interactions | 4.2 | 25 | Citations (PDF) |
| 583 | Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study | 4.4 | 50 | Citations (PDF) |
| 584 | C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy | 18.0 | 118 | Citations (PDF) |
| 585 | Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients | 0.8 | 24 | Citations (PDF) |
| 586 | Correlates of Repeat Lipid Testing in Patients With Coronary Heart Disease | 10.6 | 18 | Citations (PDF) |
| 587 | Retinol binding protein 4 and incident diabetes – the Atherosclerosis Risk in Communities Study (ARIC Study) | 0.5 | 17 | Citations (PDF) |
| 588 | Lactate and Risk of Incident Diabetes in a Case-Cohort of the Atherosclerosis Risk in Communities (ARIC) Study | 2.3 | 74 | Citations (PDF) |
| 589 | Elevated Plasma SPARC Levels Are Associated with Insulin Resistance, Dyslipidemia, and Inflammation in Gestational Diabetes Mellitus | 2.3 | 56 | Citations (PDF) |
| 590 | Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy | 3.6 | 82 | Citations (PDF) |
| 591 | FluvastatinDrugs, 2012, 64, 1305-1323 | 11.4 | 12 | Citations (PDF) |
| 592 | Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A
2
Mass and Activity at Baseline and After Rosuvastatin Therapy | 3.8 | 37 | Citations (PDF) |
| 593 | Response to Letter From Watanabe and Aizawa Regarding Article, “Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study,” by Lopez et al | 6.1 | 1 | Citations (PDF) |
| 594 | Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals | 3.2 | 458 | Citations (PDF) |
| 595 | Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects | 18.0 | 316 | Citations (PDF) |
| 596 | LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia | 3.6 | 12 | Citations (PDF) |
| 597 | Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study | 3.6 | 38 | Citations (PDF) |
| 598 | Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia | 3.6 | 14 | Citations (PDF) |
| 599 | Carotid Arterial Wall Characteristics Are Associated With Incident Ischemic Stroke But Not Coronary Heart Disease in the Atherosclerosis Risk in Communities (ARIC) Study | 5.9 | 112 | Citations (PDF) |
| 600 | Lipid-Related Markers and Cardiovascular Disease Prediction | 16.5 | 389 | Citations (PDF) |
| 601 | Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies | 2.2 | 93 | Citations (PDF) |
| 602 | Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study | 2.2 | 158 | Citations (PDF) |
| 603 | Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation | 6.1 | 144 | Citations (PDF) |
| 604 | Relation of Lipid Gene Scores to Longitudinal Trends in Lipid Levels and Incidence of Abnormal Lipid Levels Among Individuals of European Ancestry | 3.8 | 33 | Citations (PDF) |
| 605 | Racial Differences in Association of Elevated Interleukin-18 Levels With Type 2 Diabetes | 6.2 | 17 | Citations (PDF) |
| 606 | Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples | 0.8 | 53 | Citations (PDF) |
| 607 | Effect of Two Intensive Statin Regimens on Progression of Coronary Disease | 0.1 | 15 | Citations (PDF) |
| 608 | Chromosome 9p21 Single Nucleotide Polymorphisms Are Not Associated With Recurrent Myocardial Infarction in Patients With Established Coronary Artery Disease | 1.7 | 26 | Citations (PDF) |
| 609 | Combined Association of Albuminuria and Cystatin C–Based Estimated GFR With Mortality, Coronary Heart Disease, and Heart Failure Outcomes: The Atherosclerosis Risk in Communities (ARIC) Study | 1.4 | 88 | Citations (PDF) |
| 610 | Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome | 34.5 | 1,953 | Citations (PDF) |
| 611 | Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial | 2.1 | 14 | Citations (PDF) |
| 612 | The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study | 1.5 | 15 | Citations (PDF) |
| 613 | Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players | 1.5 | 19 | Citations (PDF) |
| 614 | A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies | 1.5 | 71 | Citations (PDF) |
| 615 | ApoE and the role of very low density lipoproteins in adipose tissue inflammation | 1.5 | 26 | Citations (PDF) |
| 616 | Non–high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training | 3.1 | 15 | Citations (PDF) |
| 617 | Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia | 3.1 | 14 | Citations (PDF) |
| 618 | Clinical use of genetic typing in human lipid disorders† | 3.1 | 3 | Citations (PDF) |
| 619 | AMR101, a Pure Ethyl Eicosapentaenoic Acid Omega-3 Fatty Acid: Effects on Inflammation-Associated End Points From the MARINE and ANCHOR Studies | 3.1 | 0 | Citations (PDF) |
| 620 | The Effect of Two Doses of AMR101 on Fasting Serum Triglycerides and Other Lipid Parameters in Statin-Treated Patients with Persistent High Triglycerides (≥200 and <500 mg/dL): The ANCHOR Study† | 3.1 | 1 | Citations (PDF) |
| 621 | Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, non–High-Density Lipoprotein Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Risk† | 3.1 | 0 | Citations (PDF) |
| 622 | Non–high-density lipoprotein cholesterol reporting and goal attainment in primary care | 3.1 | 14 | Citations (PDF) |
| 623 | Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study) | 3.1 | 87 | Citations (PDF) |
| 624 | Developing and assessing cardiovascular biomarkers | 4.0 | 25 | Citations (PDF) |
| 625 | Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study | 2.9 | 54 | Citations (PDF) |
| 626 | Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction | 3.1 | 19 | Citations (PDF) |
| 627 | Chronic Hyperglycemia and Subclinical Myocardial Injury | 2.3 | 127 | Citations (PDF) |
| 628 | Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci | 6.5 | 237 | Citations (PDF) |
| 629 | Outcomes of Preoperative Angiotensin-Converting Enzyme Inhibitor Therapy in Patients Undergoing Isolated Coronary Artery Bypass Grafting | 1.8 | 38 | Citations (PDF) |
| 630 | Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) | 1.8 | 321 | Citations (PDF) |
| 631 | Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure – A Pilot Study | 0.0 | 30 | Citations (PDF) |
| 632 | Prediction of Incident Heart Failure in General Practice | 4.4 | 257 | Citations (PDF) |
| 633 | ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies | 2.1 | 88 | Citations (PDF) |
| 634 | Novel Markers of Kidney Function as Predictors of ESRD, Cardiovascular Disease, and Mortality in the General Population | 1.4 | 165 | Citations (PDF) |
| 635 | Multi-Ethnic Analysis of Lipid-Associated Loci: The NHLBI CARe Project | 2.3 | 46 | Citations (PDF) |
| 636 | Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations | 2.3 | 43 | Citations (PDF) |
| 637 | Diabetes Medication Use and Blood Lactate Level among Participants with Type 2 Diabetes: The Atherosclerosis Risk in Communities Carotid MRI Study | 2.3 | 18 | Citations (PDF) |
| 638 | Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels | 18.0 | 494 | Citations (PDF) |
| 639 | Triglycerides and Cardiovascular Disease | 18.0 | 1,759 | Citations (PDF) |
| 640 | Segmental Analysis of Carotid Arterial Strain Using Speckle-Tracking | 3.4 | 31 | Citations (PDF) |
| 641 | Real-Time Co-Registration Using Novel Ultrasound Technology: Ex Vivo Validation and In Vivo Applications | 3.4 | 14 | Citations (PDF) |
| 642 | Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease | 2.3 | 172 | Citations (PDF) |
| 643 | Lipid Target Attainment by Switching Statin Monotherapy to Fenofibric Acid + Statin in Patients with Mixed Dyslipidemia and at High-/Highest-Risk for Coronary Heart Disease | 3.1 | 1 | Citations (PDF) |
| 644 | Barriers to Non-HDL-Cholesterol Goal Attainment: Exploring the Gaps in Knowledge, Attitude, and Practices of Providers* | 3.1 | 0 | Citations (PDF) |
| 645 | Extended Release Niacin/Laropiprant Lowers Atherogenic Lipids Across Patient Subgroups | 3.1 | 0 | Citations (PDF) |
| 646 | Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study) | 3.1 | 25 | Citations (PDF) |
| 647 | Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L) | 3.1 | 3 | Citations (PDF) |
| 648 | Pharmacological strategies for lowering LDL cholesterol: statins and beyond | 35.5 | 103 | Citations (PDF) |
| 649 | Effect of Two Intensive Statin Regimens on Progression of Coronary Disease | 34.5 | 852 | Citations (PDF) |
| 650 | Peripheral artery disease, biomarkers, and darapladib | 2.9 | 21 | Citations (PDF) |
| 651 | Institutional, provider, and patient correlates of low-density lipoprotein and non–high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines | 2.9 | 43 | Citations (PDF) |
| 652 | Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease | 2.9 | 53 | Citations (PDF) |
| 653 | Barriers to Non-HDL Cholesterol Goal Attainment by Providers | 2.0 | 31 | Citations (PDF) |
| 654 | White Blood Cell Count, C-Reactive Protein, and Incident Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study | 1.7 | 55 | Citations (PDF) |
| 655 | Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients | 1.8 | 19 | Citations (PDF) |
| 656 | Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN) | 2.1 | 45 | Citations (PDF) |
| 657 | Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity | 1.5 | 33 | Citations (PDF) |
| 658 | Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: The Atherosclerosis Risk in Communities (ARIC) carotid MRI study | 1.5 | 45 | Citations (PDF) |
| 659 | Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia | 1.5 | 46 | Citations (PDF) |
| 660 | Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial | 62.1 | 512 | Citations (PDF) |
| 661 | Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohortBlood, 2011, 117, 5224-5230 | 4.8 | 50 | Citations (PDF) |
| 662 | Isolated Coronary Artery Bypass Grafting in Obese Individuals - A Propensity Matched Analysis of Outcomes - | 1.7 | 36 | Citations (PDF) |
| 663 | Effect of the Cannabinoid Receptor‐1 Antagonist Rimonabant on Inflammation in Mice With Diet‐Induced Obesity | 4.0 | 24 | Citations (PDF) |
| 664 | Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities | 1.8 | 30 | Citations (PDF) |
| 665 | The Editor's Roundtable: JUPITER Follow-Up | 1.8 | 2 | Citations (PDF) |
| 666 | Usefulness of Single Nucleotide Polymorphism in Chromosome 4q25 to Predict In-Hospital and Long-Term Development of Atrial Fibrillation and Survival in Patients Undergoing Coronary Artery Bypass Grafting | 1.8 | 40 | Citations (PDF) |
| 667 | Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) | 1.8 | 340 | Citations (PDF) |
| 668 | Intramural coronary lipid injection induces atheromatous lesions expressing proinflammatory chemokines: implications for the development of a porcine model of atherosclerosis | 0.7 | 11 | Citations (PDF) |
| 669 | Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides | 2.1 | 15 | Citations (PDF) |
| 670 | Simultaneous bilateral magnetic resonance imaging of the femoral arteries in peripheral arterial disease patients | 3.4 | 6 | Citations (PDF) |
| 671 | Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of “Heart Positive,” a Randomized, Controlled Trial | 4.0 | 55 | Citations (PDF) |
| 672 | Update on therapies targeting HDL | 4.0 | 1 | Citations (PDF) |
| 673 | Nontraditional Markers of Glycemia | 6.2 | 115 | Citations (PDF) |
| 674 | CD11c Controls Herpes Simplex Virus 1 Responses To Limit Virus Replication during Primary Infection | 3.6 | 22 | Citations (PDF) |
| 675 | Association of Variation at the
ABO
Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectin | 3.8 | 92 | Citations (PDF) |
| 676 | Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study | 18.0 | 722 | Citations (PDF) |
| 677 | CD11c/CD18 Expression Is Upregulated on Blood Monocytes During Hypertriglyceridemia and Enhances Adhesion to Vascular Cell Adhesion Molecule-1 | 6.0 | 151 | Citations (PDF) |
| 678 | Nutrition and metabolism - sphingolipids and branched chain amino acids | 4.0 | 6 | Citations (PDF) |
| 679 | Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study | 2.2 | 57 | Citations (PDF) |
| 680 | Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes | 6.0 | 50 | Citations (PDF) |
| 681 | Sources of Variability in Measurements of Cardiac Troponin T in a Community-Based Sample: The Atherosclerosis Risk in Communities Study | 1.1 | 85 | Citations (PDF) |
| 682 | Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque | 25.2 | 202 | Citations (PDF) |
| 683 | Racial Differences in Glycemic Markers: A Cross-sectional Analysis of Community-Based Data | 9.6 | 182 | Citations (PDF) |
| 684 | Therapy and clinical trials: HDL-cholesterol and niacin therapy – past, present, and future | 4.0 | 4 | Citations (PDF) |
| 685 | Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediatorsBlood, 2010, 115, 5289-5299 | 4.8 | 124 | Citations (PDF) |
| 686 | Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy | 1.8 | 22 | Citations (PDF) |
| 687 | The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in Caucasians with hypertension or without diabetes: the ARIC Study | 2.9 | 12 | Citations (PDF) |
| 688 | Biological, clinical and population relevance of 95 loci for blood lipids | 37.9 | 3,470 | Citations (PDF) |
| 689 | A 1-Year Lifestyle Intervention for Weight Loss in Individuals With Type 2 Diabetes Reduces High C-Reactive Protein Levels and Identifies Metabolic Predictors of Change | 6.2 | 95 | Citations (PDF) |
| 690 | Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels | 2.9 | 260 | Citations (PDF) |
| 691 | CD11c Expression in Adipose Tissue and Blood and Its Role in Diet-Induced Obesity | 6.0 | 133 | Citations (PDF) |
| 692 | Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study | 4.9 | 221 | Citations (PDF) |
| 693 | Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients | 2.9 | 22 | Citations (PDF) |
| 694 | Marine ω-3 Fatty Acid Intake | 6.2 | 26 | Citations (PDF) |
| 695 | Association of Circulating Matrix Metalloproteinases With Carotid Artery Characteristics | 6.0 | 44 | Citations (PDF) |
| 696 | Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease | 2.4 | 32 | Citations (PDF) |
| 697 | METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis | 2.3 | 3 | Citations (PDF) |
| 698 | Intercellular Adhesion Molecule-1 G241R Polymorphism Predicts Risk of Incident Ischemic Stroke | 5.9 | 18 | Citations (PDF) |
| 699 | High-Molecular-Weight Adiponectin and the Risk of Type 2 Diabetes in the ARIC Study | 4.0 | 104 | Citations (PDF) |
| 700 | ARTERIAL WALL CHARACTERISTICS ARE ASSOCIATED WITH INCIDENT CARDIOVASCULAR DISEASE: AN ANALYSIS FROM THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY | 2.3 | 0 | Citations (PDF) |
| 701 | Carotid Intima-Media Thickness and Presence or Absence of Plaque Improves Prediction of Coronary Heart Disease Risk | 2.3 | 867 | Citations (PDF) |
| 702 | Safety of extended-release niacin/laropiprant in patients with dyslipidemia | 3.1 | 30 | Citations (PDF) |
| 703 | Changes in Prescription Patterns for Ezetimibe/Simvastatin, Ezetimibe and Statin, and Statin Therapies and Expected Effects on LDL-C Reduction | 3.1 | 1 | Citations (PDF) |
| 704 | Management of Lp(a) | 3.1 | 58 | Citations (PDF) |
| 705 | Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression | 3.1 | 15 | Citations (PDF) |
| 706 | Preoperative Statin Therapy Decreases Risk of Postoperative Renal Insufficiency | 5.3 | 42 | Citations (PDF) |
| 707 | Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies | 62.1 | 583 | Citations (PDF) |
| 708 | Genetic Determinants of Plasma Von Willebrand Factor Antigen Levels: A Target Gene SNP and Haplotype Analysis of the ARIC CohortBlood, 2010, 116, 4310-4310 | 4.8 | 0 | Citations (PDF) |
| 709 | Strategies for Optimizing Lipid Management | 2.5 | 0 | Citations (PDF) |
| 710 | Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study | 4.1 | 16 | Citations (PDF) |
| 711 | Advances in Lipid Testing and Management in Patients with Diabetes Mellitus | 3.3 | 3 | Citations (PDF) |
| 712 | Commentary | 1.1 | 0 | Citations (PDF) |
| 713 | ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease | 18.0 | 31 | Citations (PDF) |
| 714 | Inflammation, Adipose Tissue, and T Cells: What Is the “Straight Skinny” on Lean Versus Fat Mice? | 13.1 | 1 | Citations (PDF) |
| 715 | Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study | 3.6 | 85 | Citations (PDF) |
| 716 | Functional Role of CD11c
+
Monocytes in Atherogenesis Associated With Hypercholesterolemia | 18.0 | 223 | Citations (PDF) |
| 717 | Lipoprotein-Associated Phospholipase A
2
and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study | 5.9 | 81 | Citations (PDF) |
| 718 | Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience | 0.8 | 24 | Citations (PDF) |
| 719 | Inflammatory Protein Levels and Depression Screening After Coronary Stenting Predict Major Adverse Coronary Events | 2.2 | 9 | Citations (PDF) |
| 720 | Criteria for Evaluation of Novel Markers of Cardiovascular Risk | 18.0 | 1,065 | Citations (PDF) |
| 721 | National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease | 1.1 | 410 | Citations (PDF) |
| 722 | Impact of Adding a Single Allele in the 9p21 Locus to Traditional Risk Factors on Reclassification of Coronary Heart Disease Risk and Implications for Lipid-Modifying Therapy in the Atherosclerosis Risk in Communities Study | 3.8 | 91 | Citations (PDF) |
| 723 | Correlates of Carotid Plaque Presence and Composition as Measured by MRI | 2.9 | 57 | Citations (PDF) |
| 724 | The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis | 2.0 | 35 | Citations (PDF) |
| 725 | Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy | 1.8 | 91 | Citations (PDF) |
| 726 | Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia | 1.8 | 61 | Citations (PDF) |
| 727 | Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study) | 1.8 | 63 | Citations (PDF) |
| 728 | Improved Horvitz–Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology | 0.3 | 128 | Citations (PDF) |
| 729 | Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis | 1.8 | 44 | Citations (PDF) |
| 730 | Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome | 2.9 | 186 | Citations (PDF) |
| 731 | ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease | 2.3 | 54 | Citations (PDF) |
| 732 | Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population | 2.3 | 55 | Citations (PDF) |
| 733 | Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia | 3.1 | 69 | Citations (PDF) |
| 734 | Efficacy and tolerability of multidrug therapy for hypertriglyceridemia | 3.1 | 4 | Citations (PDF) |
| 735 | Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD) | 2.4 | 16 | Citations (PDF) |
| 736 | Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category | 1.9 | 9 | Citations (PDF) |
| 737 | Using the Whole Cohort in the Analysis of Case-Cohort Data | 3.3 | 150 | Citations (PDF) |
| 738 | Development and Validation of a Patient Self-assessment Score for Diabetes Risk | 9.6 | 302 | Citations (PDF) |
| 739 | What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? | 4.0 | 29 | Citations (PDF) |
| 740 | Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations | 2.2 | 6 | Citations (PDF) |
| 741 | Monocyte integrin CD11c/CD18 is a functional biomarker for risk of cardiovascular disease | 0.6 | 0 | Citations (PDF) |
| 742 | Monocyte CD11c/CD18 expression is upregulated postprandially and mediates firm arrest on VCAM‐1 | 0.6 | 0 | Citations (PDF) |
| 743 | Lipoprotein-associated phospholipase A2: Risk marker or target of therapy? | 1.7 | 0 | Citations (PDF) |
| 744 | Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study | 3.0 | 91 | Citations (PDF) |
| 745 | Increased Myocardial Susceptibility to Repetitive Ischemia With High‐fat diet‐induced Obesit | 4.0 | 32 | Citations (PDF) |
| 746 | How to identify patients with vulnerable plaques | 4.5 | 7 | Citations (PDF) |
| 747 | Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins | 1.8 | 97 | Citations (PDF) |
| 748 | Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix. | 1.8 | 165 | Citations (PDF) |
| 749 | The Editor’s Roundtable: Atherosclerosis Regression | 1.8 | 7 | Citations (PDF) |
| 750 | Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (from the SEACOAST I Study) | 1.8 | 88 | Citations (PDF) |
| 751 | The Editor's Roundtable: Lipid Management Beyond Statins—Reducing Residual Cardiovascular Risk | 1.8 | 10 | Citations (PDF) |
| 752 | Does Preoperative Statin Therapy Improve Outcomes in Patients Undergoing Isolated Cardiac Valve Surgery? | 1.8 | 23 | Citations (PDF) |
| 753 | The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent | 2.3 | 212 | Citations (PDF) |
| 754 | Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients | 2.3 | 103 | Citations (PDF) |
| 755 | A case report of myopathy from consumption of red yeast rice | 3.1 | 23 | Citations (PDF) |
| 756 | Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses | 3.1 | 22 | Citations (PDF) |
| 757 | Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study | 3.1 | 39 | Citations (PDF) |
| 758 | Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non–HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein | 3.1 | 13 | Citations (PDF) |
| 759 | Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery | 2.9 | 73 | Citations (PDF) |
| 760 | Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease | 2.9 | 84 | Citations (PDF) |
| 761 | Platelet reactivity and response to aspirin in subjects with the metabolic syndrome | 2.9 | 44 | Citations (PDF) |
| 762 | Relationship of Alcohol Consumption and Type of Alcoholic Beverage Consumed With Plasma Lipid Levels: Differences Between Whites and African Americans of the ARIC Study | 1.7 | 70 | Citations (PDF) |
| 763 | Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G−765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study | 1.5 | 56 | Citations (PDF) |
| 764 | Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: The Atherosclerosis Risk in Communities (ARIC) Study | 1.5 | 19 | Citations (PDF) |
| 765 | Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors | 1.5 | 28 | Citations (PDF) |
| 766 | Developmental Control of Integrin Expression Regulates Th2 Effector Homing | 0.6 | 18 | Citations (PDF) |
| 767 | Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography | 18.0 | 200 | Citations (PDF) |
| 768 | Response to Letters Regarding Article, “Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound–Derived Coronary Atheroma Burden” | 18.0 | 0 | Citations (PDF) |
| 769 | Association of Lactate With Blood Pressure Before and After Rapid Weight Loss | 2.0 | 44 | Citations (PDF) |
| 770 | APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels | 2.9 | 22 | Citations (PDF) |
| 771 | Association of the Complement Factor H Y402H Polymorphism With Cardiovascular Disease Is Dependent Upon Hypertension Status: The ARIC Study | 2.0 | 31 | Citations (PDF) |
| 772 | Regulation of LFA-1–dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteinsBlood, 2008, 111, 3607-3614 | 4.8 | 56 | Citations (PDF) |
| 773 | Expression, activation, and function of integrin αMβ2 (Mac-1) on neutrophil-derived microparticlesBlood, 2008, 112, 2327-2335 | 4.8 | 183 | Citations (PDF) |
| 774 | Regression Of Atherosclerosis: Where Are We Now, And Where Are We Going? | 1.5 | 0 | Citations (PDF) |
| 775 | Peroxisome proliferator–activated receptor α genetic variation interacts with n−6 and long-chain n−3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study | 4.7 | 52 | Citations (PDF) |
| 776 | Endothelial Domes Encapsulate Adherent Neutrophils and Minimize Increases in Vascular Permeability in Paracellular and Transcellular Emigration | 2.3 | 105 | Citations (PDF) |
| 777 | The α
x
β
2
integrin CD11c is a potent costimulator of CD8 T cell responses | 0.6 | 0 | Citations (PDF) |
| 778 | A Prospective Study of Plasma Ferritin Level and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study | 3.3 | 117 | Citations (PDF) |
| 779 | Interaction Effects of High-Density Lipoprotein Metabolism Gene Variation and Alcohol Consumption on Coronary Heart Disease Risk: The Atherosclerosis Risk in Communities Study | 1.6 | 19 | Citations (PDF) |
| 780 | An Annual, Prospective, International Study of Outpatients With Cardiovascular Disease or Risk Factors | 0.2 | 2 | Citations (PDF) |
| 781 | Increasing Prevalence of Obesity and Clustered Cardiometabolic Risk: Can Treatment of the Underlying Cause Reverse the Trends? | 0.2 | 5 | Citations (PDF) |
| 782 | Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study | 2.7 | 378 | Citations (PDF) |
| 783 | L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion | 1.5 | 32 | Citations (PDF) |
| 784 | Pro-apoptotic low-density lipoprotein subfractions in type II diabetes | 1.5 | 34 | Citations (PDF) |
| 785 | Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults | 1.5 | 60 | Citations (PDF) |
| 786 | Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study | 1.5 | 46 | Citations (PDF) |
| 787 | T-Cell Accumulation and Regulated on Activation, Normal T Cell Expressed and Secreted Upregulation in Adipose Tissue in Obesity | 18.0 | 626 | Citations (PDF) |
| 788 | Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy | 2.1 | 154 | Citations (PDF) |
| 789 | Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study | 1.3 | 6 | Citations (PDF) |
| 790 | A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin | 7.3 | 375 | Citations (PDF) |
| 791 | Genetic variation and decreased risk for obesity in the Atherosclerosis Risk in Communities Study | 4.5 | 25 | Citations (PDF) |
| 792 | Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study) | 1.8 | 188 | Citations (PDF) |
| 793 | Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels | 1.8 | 66 | Citations (PDF) |
| 794 | Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia | 1.8 | 28 | Citations (PDF) |
| 795 | Treatment of Dyslipidemia to Reduce Cardiovascular Risk in Patients with Multiple Risk Factors | 1.3 | 16 | Citations (PDF) |
| 796 | Role of Biomarkers in Developing New Therapies for Vascular Disease | 2.3 | 14 | Citations (PDF) |
| 797 | Peripheral Arterial Occlusive Disease: Magnetic Resonance Imaging and the Role of Aggressive Medical Management | 2.3 | 21 | Citations (PDF) |
| 798 | Prevalence of Metabolic Syndrome and Associated Risk Factors in Asian Indians | 1.4 | 37 | Citations (PDF) |
| 799 | P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: The Atherosclerosis Risk In Communities Study | 1.5 | 47 | Citations (PDF) |
| 800 | Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction | 3.5 | 107 | Citations (PDF) |
| 801 | Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II | 2.9 | 93 | Citations (PDF) |
| 802 | Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia | 1.6 | 18 | Citations (PDF) |
| 803 | Effectiveness and Tolerability of Adding Ezetimibe to Niacin-Based Regimens for Treatment of Primary Hyperlipidemia | 3.3 | 18 | Citations (PDF) |
| 804 | Leptin and incident type 2 diabetes: risk or protection? | 7.5 | 104 | Citations (PDF) |
| 805 | Response to comment on: Schmidt MI, Duncan BB, Vigo A et al. (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086–2096 | 7.5 | 0 | Citations (PDF) |
| 806 | Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study | 7.5 | 45 | Citations (PDF) |
| 807 | Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events | 4.7 | 16 | Citations (PDF) |
| 808 | Application of Recent Definitions of the Metabolic Syndrome to Survey Data From the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II) | 2.3 | 3 | Citations (PDF) |
| 809 | Combination Therapy with Statins and Omega-3 Fatty Acids | 1.8 | 73 | Citations (PDF) |
| 810 | Point: High-Sensitivity C-Reactive Protein and Cardiac C-Reactive Protein Assays: Is There a Need to Differentiate? | 1.1 | 12 | Citations (PDF) |
| 811 | Eotaxin and Obesity | 4.0 | 125 | Citations (PDF) |
| 812 | Apolipoprotein E Polymorphisms Predict Low Density Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary Heart Disease in 12,491 ARIC Study Participants | 3.3 | 127 | Citations (PDF) |
| 813 | An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers | 8.1 | 327 | Citations (PDF) |
| 814 | Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis | 16.5 | 1,896 | Citations (PDF) |
| 815 | Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients | 2.1 | 103 | Citations (PDF) |
| 816 | Apolipoprotein E Genotype and Incident Ischemic Stroke | 5.9 | 15 | Citations (PDF) |
| 817 | Center For Cardiovascular Disease Prevention: Risk Assessment And Reduction | 1.5 | 0 | Citations (PDF) |
| 818 | Discussion | 3.0 | 1 | Citations (PDF) |
| 819 | Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations | 1.8 | 260 | Citations (PDF) |
| 820 | Cardiometabolic risk assessment: An approach to the prevention of cardiovascular disease and diabetes mellitus | 1.3 | 35 | Citations (PDF) |
| 821 | Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk | 4.7 | 7 | Citations (PDF) |
| 822 | Comparison of the Instructional Efficacy of Internet-Based CME With Live Interactive CME Workshops | 16.5 | 348 | Citations (PDF) |
| 823 | A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study† | 2.2 | 107 | Citations (PDF) |
| 824 | PLAC™ test for identification of individuals at increased risk for coronary heart disease | 3.0 | 22 | Citations (PDF) |
| 825 | The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study | 6.2 | 1,015 | Citations (PDF) |
| 826 | Multiplexed Analysis of Biomarkers Related to Obesity and the Metabolic Syndrome in Human Plasma, Using the Luminex-100 System | 1.1 | 170 | Citations (PDF) |
| 827 | Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study | 8.1 | 252 | Citations (PDF) |
| 828 | Lipids and CVD management: towards a global consensus | 2.2 | 83 | Citations (PDF) |
| 829 | Changing lipid-lowering guidelines: whom to treat and how low to go | 1.3 | 5 | Citations (PDF) |
| 830 | Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study | 1.5 | 152 | Citations (PDF) |
| 831 | Markers of inflammation and their clinical significance | 3.1 | 143 | Citations (PDF) |
| 832 | Conditional Risk Factors for Atherosclerosis | 3.7 | 83 | Citations (PDF) |
| 833 | Extra domain A and type III connecting segment of fibronectin in assembly and cleavage | 2.1 | 17 | Citations (PDF) |
| 834 | Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study | 2.9 | 240 | Citations (PDF) |
| 835 | A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis | 2.3 | 151 | Citations (PDF) |
| 836 | Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the atherosclerosis risk in communities (ARIC) Study | 1.9 | 16 | Citations (PDF) |
| 837 | Measurement of Cholesterol | 18.0 | 38 | Citations (PDF) |
| 838 | Adiponectin, Inflammation, and the Expression of the Metabolic Syndrome in Obese Individuals: The Impact of Rapid Weight Loss through Caloric Restriction | 4.0 | 264 | Citations (PDF) |
| 839 | The Virulence Function of
Streptococcus pneumoniae
Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection | 0.6 | 108 | Citations (PDF) |
| 840 | Lipoprotein-Associated Phospholipase A
2
, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study | 18.0 | 611 | Citations (PDF) |
| 841 | Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion | 3.5 | 114 | Citations (PDF) |
| 842 | Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia | 3.0 | 45 | Citations (PDF) |
| 843 | Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia | 3.0 | 123 | Citations (PDF) |
| 844 | Characteristics of US adults with the metabolic syndrome and therapeutic implications | 4.5 | 32 | Citations (PDF) |
| 845 | Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia | 1.8 | 190 | Citations (PDF) |
| 846 | Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia | 1.8 | 52 | Citations (PDF) |
| 847 | Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study) | 1.8 | 158 | Citations (PDF) |
| 848 | Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease | 2.1 | 9 | Citations (PDF) |
| 849 | Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy | 4.7 | 18 | Citations (PDF) |
| 850 | ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients | 4.7 | 2 | Citations (PDF) |
| 851 | Endothelial lipase and cholesterol metabolism | 4.7 | 14 | Citations (PDF) |
| 852 | Role of selective cholesterol absorption inhibition in the management of dyslipidemia | 4.7 | 7 | Citations (PDF) |
| 853 | Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging | 1.8 | 58 | Citations (PDF) |
| 854 | Management of metabolic syndrome: statins | 3.5 | 7 | Citations (PDF) |
| 855 | Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial | 2.7 | 27 | Citations (PDF) |
| 856 | Loss of LFA-1, but not Mac-1, Protects MRL/MpJ-Faslpr Mice from Autoimmune Disease | 3.4 | 80 | Citations (PDF) |
| 857 | Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction | 2.9 | 17 | Citations (PDF) |
| 858 | Effects of PPAR??, ?? and ?? haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study | 6.7 | 51 | Citations (PDF) |
| 859 | Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1 | 10.6 | 87 | Citations (PDF) |
| 860 | Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1 | 10.6 | 67 | Citations (PDF) |
| 861 | Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease | 1.8 | 135 | Citations (PDF) |
| 862 | B vitamin status and inflammatory markers | 1.5 | 59 | Citations (PDF) |
| 863 | Platelet–monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with αIIbβ3 and αMβ2, in coronary stenting | 2.3 | 49 | Citations (PDF) |
| 864 | Role of lipid and lipoprotein profiles in risk assessment and therapy | 2.9 | 57 | Citations (PDF) |
| 865 | Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS) | 2.9 | 69 | Citations (PDF) |
| 866 | Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia | 18.0 | 659 | Citations (PDF) |
| 867 | Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study | 1.5 | 64 | Citations (PDF) |
| 868 | Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome | 2.7 | 40 | Citations (PDF) |
| 869 | From Vulnerable Plaque to Vulnerable Patient | 18.0 | 2,451 | Citations (PDF) |
| 870 | From Vulnerable Plaque to Vulnerable Patient | 18.0 | 1,605 | Citations (PDF) |
| 871 | Risk for Myopathy With Statin Therapy in High-Risk Patients | 8.1 | 413 | Citations (PDF) |
| 872 | Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease | 18.0 | 55 | Citations (PDF) |
| 873 | Long-Term, Randomized Clinical Trial of Two Diets in the Metabolic Syndrome and Type 2 Diabetes | 6.2 | 36 | Citations (PDF) |
| 874 | Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription | 18.0 | 157 | Citations (PDF) |
| 875 | Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism | 7.5 | 224 | Citations (PDF) |
| 876 | Host Resistance of CD18 Knockout Mice against Systemic Infection with
Listeria monocytogenes | 2.7 | 19 | Citations (PDF) |
| 877 | Plasma Lipid Profile and Incident Ischemic Stroke | 5.9 | 293 | Citations (PDF) |
| 878 | Role of non–high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials | 1.6 | 21 | Citations (PDF) |
| 879 | Raising high-density lipoprotein cholesterol: where are we now? | 0.1 | 0 | Citations (PDF) |
| 880 | Roles of neutrophil β2 integrins in kinetics of bacteremia, extravasation, and tick acquisition of Anaplasma phagocytophila in miceBlood, 2003, 101, 3257-3264 | 4.8 | 20 | Citations (PDF) |
| 881 | Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients | 3.6 | 268 | Citations (PDF) |
| 882 | Ezetimibe: efficacy and safety in clinical trials | 0.1 | 32 | Citations (PDF) |
| 883 | Evolving concepts and a new approach for management of hyperlipidemia | 0.1 | 5 | Citations (PDF) |
| 884 | Role of α4Integrin and VCAM-1 in CD18-Independent Neutrophil Migration Across Mouse Cardiac Endothelium | 13.1 | 106 | Citations (PDF) |
| 885 | Control of leukocyte rolling velocity in TNF-α–induced inflammation by LFA-1 and Mac-1 | 4.8 | 188 | Citations (PDF) |
| 886 | Cardiovascular risk factors associated with immunosuppression in renal transplantation | 2.2 | 17 | Citations (PDF) |
| 887 | Use of Denaturing HPLC to Provide Efficient Detection of Mutations Causing Familial Hypercholesterolemia | 1.1 | 29 | Citations (PDF) |
| 888 | VASCULAR CELL ADHESION MOLECULE-1 EXPRESSION AND HEMATOPOIETIC SUPPORTIVE CAPACITY OF IMMORTALIZED MURINE STROMAL CELL LINES DERIVED FROM FETAL LIVER AND ADULT BONE MARROW | 1.5 | 6 | Citations (PDF) |
| 889 | LPL polymorphism predicts stroke risk in men | 3.1 | 42 | Citations (PDF) |
| 890 | Statins and inflammatory markers | 4.7 | 20 | Citations (PDF) |
| 891 | Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin | 3.7 | 44 | Citations (PDF) |
| 892 | Impact of weight loss on the metabolic syndrome | 4.5 | 173 | Citations (PDF) |
| 893 | Kinetics of CD11b/CD18 Up-Regulation During Infection with the Agent of Human Granulocytic Ehrlichiosis in Mice | 3.2 | 33 | Citations (PDF) |
| 894 | A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin | 1.5 | 55 | Citations (PDF) |
| 895 | The Evolving Role of High-Density Lipoprotein in Reducing Cardiovascular Risk | 1.1 | 4 | Citations (PDF) |
| 896 | Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins | 2.0 | 168 | Citations (PDF) |
| 897 | Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis | 2.7 | 72 | Citations (PDF) |
| 898 | Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice | 3.5 | 77 | Citations (PDF) |
| 899 | Treating mixed dyslipidemias: Why and how | 2.0 | 11 | Citations (PDF) |
| 900 | Case 4: type 2 diabetes, hypertension, and dyslipidemia11This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the A. Webb Roberts Center for Continuing Education of Baylor Health Care System, Dallas, and Medsite, Inc. The A. Webb Roberts Center for Continuing Education of Baylor Health Care System, Dallas, is accredited by the ACCME to provide continuing medical education | 1.8 | 0 | Citations (PDF) |
| 901 | Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels | 1.8 | 163 | Citations (PDF) |
| 902 | Newer risk markers and surrogate endpoints in atherosclerosis management | 2.0 | 5 | Citations (PDF) |
| 903 | EFFECT OF SIROLIMUS ON THE METABOLISM OF ApoB100- CONTAINING LIPOPROTEINS IN RENAL TRANSPLANT PATIENTS1 | 2.1 | 121 | Citations (PDF) |
| 904 | Mechanism of chronic obstructive uropathy: Increased expression of apoptosis-promoting molecules | 5.3 | 67 | Citations (PDF) |
| 905 | Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia | 1.8 | 26 | Citations (PDF) |
| 906 | Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure | 4.7 | 0 | Citations (PDF) |
| 907 | A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy | 3.7 | 35 | Citations (PDF) |
| 908 | A chronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies | 3.5 | 157 | Citations (PDF) |
| 909 | Hydrogen peroxide induces LFA-1-dependent neutrophil adherence to cardiac myocytes | 3.5 | 16 | Citations (PDF) |
| 910 | Platelet Glycoprotein Ibα Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18) | 9.3 | 596 | Citations (PDF) |
| 911 | Primary Prevention of Coronary Heart Disease | 4.0 | 80 | Citations (PDF) |
| 912 | Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data | 8.1 | 70 | Citations (PDF) |
| 913 | Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin | 2.3 | 77 | Citations (PDF) |
| 914 | Apolipoprotein E genotypes and response of plasma lipids and progression–regression of coronary atherosclerosis to lipid-lowering drug therapy | 2.3 | 92 | Citations (PDF) |
| 915 | Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice | 3.6 | 32 | Citations (PDF) |
| 916 | Decreased neointimal formation in Mac-1–/– mice reveals a role for inflammation in vascular repair after angioplasty | 10.6 | 219 | Citations (PDF) |
| 917 | Primary Prevention of Coronary Heart Disease | 4.0 | 17 | Citations (PDF) |
| 918 | LFA-1 (CD11a/CD18) triggers hydrogen peroxide production by canine neutrophils | 2.9 | 22 | Citations (PDF) |
| 919 | Myocardial infarction and remodeling in mice: effect of reperfusion | 3.5 | 81 | Citations (PDF) |
| 920 | Effect of Moderate Alcohol Consumption on Hypertriglyceridemia | 8.1 | 64 | Citations (PDF) |
| 921 | Adhesion molecules in cardiovascular disease | 0.8 | 3 | Citations (PDF) |
| 922 | Reducing atherothrombotic events in high-risk patients: Recent data on therapy with statins and fatty acids | 4.7 | 4 | Citations (PDF) |
| 923 | Inflammation and lipid-lowering treatment | 2.9 | 1 | Citations (PDF) |
| 924 | Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins | 1.5 | 168 | Citations (PDF) |
| 925 | Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events | 1.5 | 35 | Citations (PDF) |
| 926 | EFFECT OF SIROLIMUS ON PLASMA LIPID AND LIPOPROTEIN LEVELS AND METABOLISM IN RENAL TRANSPLANT PATIENTS | 2.1 | 5 | Citations (PDF) |
| 927 | Endothelial α2,6-Linked Sialic Acid Inhibits VCAM-1- Dependent Adhesion Under Flow Conditions | 0.6 | 47 | Citations (PDF) |
| 928 | Low-density lipoproteins and risk for coronary artery disease | 1.8 | 307 | Citations (PDF) |
| 929 | Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol | 5.6 | 32 | Citations (PDF) |
| 930 | Cytokines and the Microcirculation in Ischemia and Reperfusion | 3.8 | 174 | Citations (PDF) |
| 931 | Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion | 6.0 | 199 | Citations (PDF) |
| 932 | Maximizing the Cost-effectiveness of Lipid-Lowering Therapy | 8.1 | 70 | Citations (PDF) |
| 933 | Lipid Treatment and Survival After Heart Transplantation | 2.3 | 2 | Citations (PDF) |
| 934 | Lesion Progression, Regression, and Stability With Fluvastatin in the Lipoprotein and Coronary Atherosclerosis Study | 2.3 | 1 | Citations (PDF) |
| 935 | Overview | 2.2 | 0 | Citations (PDF) |
| 936 | Molecular Markers for Atherosclerosis | 2.2 | 4 | Citations (PDF) |
| 937 | Effects of lipid lowering therapy on progression of coronary and carotid artery disease | 4.0 | 48 | Citations (PDF) |
| 938 | Overview | 2.2 | 0 | Citations (PDF) |
| 939 | Molecular markers for atherosclerosis | 2.2 | 6 | Citations (PDF) |
| 940 | Phagocytes in Ischemia Injury | 4.0 | 9 | Citations (PDF) |
| 941 | Effects of Fluvastatin on Coronary Atherosclerosis in Patients With Mild to Moderate Cholesterol Elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]) | 1.8 | 320 | Citations (PDF) |
| 942 | Induction of Monocyte Chemoattractant Protein-1 in the Small Veins of the Ischemic and Reperfused Canine Myocardium | 18.0 | 152 | Citations (PDF) |
| 943 | Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases | 18.0 | 1,186 | Citations (PDF) |
| 944 | LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. | 10.6 | 276 | Citations (PDF) |
| 945 | Levels of soluble cell adhesion molecules in patients with dyslipidemia | 2.3 | 1 | Citations (PDF) |
| 946 | Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry | 1.8 | 19 | Citations (PDF) |
| 947 | The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia | 2.8 | 31 | Citations (PDF) |
| 948 | Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia | 18.0 | 264 | Citations (PDF) |
| 949 | Association of Neutrophils With Platelet Aggregates in Unstable Angina | 18.0 | 26 | Citations (PDF) |
| 950 | Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium | 3.1 | 64 | Citations (PDF) |
| 951 | Myocardial ischemia and reperfusion: a murine model | 3.5 | 258 | Citations (PDF) |
| 952 | Cloning and comparative sequence analysis of the gene encoding canine intercellular adhesion molecule-1 (ICAM-1) | 2.3 | 13 | Citations (PDF) |
| 953 | Cardiac Allograft Survival in Mice Deficient in Intercellular Adhesion Molecule–1 | 18.0 | 43 | Citations (PDF) |
| 954 | Dietary Treatment of Hyperlipidemia | 2.2 | 0 | Citations (PDF) |
| 955 | Baseline characteristics of subjects in the lipoprotein and coronary atherosclerosis study (LCAS) with fluvastatin | 1.8 | 17 | Citations (PDF) |
| 956 | Regulation of ICAM-1 and IL-6 in Myocardial Ischemia: Effect of Reperfusion a | 4.0 | 55 | Citations (PDF) |
| 957 | Increases in Lung Tissue Expression of Intercellular Adhesion Molecule-1 are Associated with Hyperoxic Lung Injury and Inflammation in Mice | 3.8 | 63 | Citations (PDF) |
| 958 | Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. | 7.5 | 560 | Citations (PDF) |
| 959 | Gene targeting yields a CD18-mutant mouse for study of inflammation. | 0.6 | 208 | Citations (PDF) |
| 960 | Characterization of the murine Icam-1 gene | 2.8 | 37 | Citations (PDF) |
| 961 | Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations | 2.3 | 128 | Citations (PDF) |
| 962 | Lipoprotein(a) and apolipoprotein changes after cardiac transplantation | 2.3 | 45 | Citations (PDF) |
| 963 | Assignment of the gene for intercellular adhesion molecule-1 (Icam-1) to proximal mouse chromosome 9 | 2.8 | 21 | Citations (PDF) |
| 964 | Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant | 1.8 | 194 | Citations (PDF) |
| 965 | Deletion and linkage mapping of eight markers from the proximal short arm of chromosome 6 | 2.8 | 20 | Citations (PDF) |
| 966 | Nucleotide sequence of the cDNA for murine intercellular adhesion molecul-1 (ICAM-1) | 15.5 | 44 | Citations (PDF) |
| 967 | Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels | 16.5 | 228 | Citations (PDF) |
| 968 | A human single copy DNA probe (ZB6-1) detects multiple polymorphisms on 6q | 15.5 | 1 | Citations (PDF) |
| 969 | Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis | 9.1 | 32 | Citations (PDF) |
| 970 | Delayed recovery of severely “stunned” myocardium with the support of a left ventricular assist device after coronary artery bypass graft surgery | 2.3 | 55 | Citations (PDF) |
| 971 | Bridging the cost-effectiveness gap in cardiovascular disease prevention for statin-intolerant patients | 2.0 | 0 | Citations (PDF) |
| 972 | Natriuretic Peptide Cut Points for Heart Failure Classification in Individuals With and Without Obesity | 4.4 | 2 | Citations (PDF) |
| 973 | Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients | 2.3 | 33 | Citations (PDF) |
| 974 | The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications | 2.2 | 12 | Citations (PDF) |
| 975 | Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT | 2.0 | 2 | Citations (PDF) |
| 976 | Age-related variations in HbA1c improvements: insights from a telehealth-supported community-based intervention | 0.1 | 0 | Citations (PDF) |
| 977 | Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up | 2.3 | 2 | Citations (PDF) |
| 978 | Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM | 2.8 | 0 | Citations (PDF) |
| 979 | Reducing Cardiovascular Disease Risk in Obesity | 2.3 | 0 | Citations (PDF) |
| 980 | Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT | 2.0 | 1 | Citations (PDF) |
| 981 | Proteomic Signatures of Cardiac Dysfunction Among People With Diabetes: The Atherosclerosis Risk in Communities Study | 4.4 | 1 | Citations (PDF) |
| 982 | The impact of genetic testing on physician practice in specialized cardiovascular clinics | 3.1 | 0 | Citations (PDF) |
| 983 | ‘U’r-in(e)!—urine albumin-creatinine ratio: the old kid on a new block! | 2.0 | 0 | Citations (PDF) |
| 984 | The evolving therapeutic landscape of PCSK9 inhibition | 1.5 | 0 | Citations (PDF) |
| 985 | Baseline Characteristics and Rationale of the SHASTA-3 and SHASTA-4 Phase 3 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia | 9.1 | 0 | Citations (PDF) |
| 986 | Comparison of different “familial chylomicronemia syndrome” clinical diagnosis scoring systems in patients with persistent chylomicronemia | 3.1 | 0 | Citations (PDF) |
| 987 | CAC Screening for Elevated Lipoprotein(a) | 2.3 | 0 | Citations (PDF) |
| 988 | Rethinking “Very High-Risk” ASCVD | 1.3 | 0 | Citations (PDF) |
| 989 | Association of infection frequency and incident clonal hematopoiesis of indeterminant potential | 0.4 | 2 | Citations (PDF) |
| 990 | 26-A-13235-ACC LOWER SERUM POTASSIUM IS ASSOCIATED WITH HIGHER RISK OF HYPERTENSION, HEART FAILURE AND MORTALITY: ALLOFUS RESEARCH PROGRAM | 2.3 | 0 | Citations (PDF) |
| 991 | 26-A-20511-ACC HIGH CORRELATION BETWEEN SERUM AND PLASMA LIPOPROTEIN(A) MEASUREMENTS: ARIC STUDY | 2.3 | 0 | Citations (PDF) |
| 992 | Coronary Computed Tomography and Artificial Intelligence–based Plaque Analysis | 4.7 | 0 | Citations (PDF) |
| 993 | Eicosapentaenoic acid ethyl ester cardioprotection: beyond triglycerides | 2.2 | 0 | Citations (PDF) |
| 994 | Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The
SPRINT
Trial | 4.5 | 0 | Citations (PDF) |
| 995 | Disrupting clinical inertia: Personalizing cardiovascular risk to transform cardiometabolic care in the real world | 2.8 | 0 | Citations (PDF) |
| 996 | Correlation between serum and plasma lipoprotein(a) measurements: ARIC study | 3.1 | 0 | Citations (PDF) |
| 997 | Reframing the cardiovascular patient as a brain at risk | 2.8 | 0 | Citations (PDF) |
| 998 | Baseline Characteristics and Rationale of SHASTA-3, -4: Randomized, Double-Blind, Phase 3 Studies of Plozasiran in Severe Hypertriglyceridemia | 3.1 | 0 | Citations (PDF) |
